{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,24]],"date-time":"2026-06-24T14:48:32Z","timestamp":1782312512459,"version":"3.54.5"},"reference-count":217,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2012,4,13]],"date-time":"2012-04-13T00:00:00Z","timestamp":1334275200000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Blood Cancer Journal"],"DOI":"10.1038\/bcj.2012.8","type":"journal-article","created":{"date-parts":[[2012,4,13]],"date-time":"2012-04-13T13:18:17Z","timestamp":1334323097000},"page":"e65-e65","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":23,"title":["Pediatric T- and NK-cell lymphomas: new biologic insights and treatment strategies"],"prefix":"10.1038","volume":"2","author":[{"given":"N K","family":"El-Mallawany","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J K","family":"Frazer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P","family":"Van Vlierberghe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A A","family":"Ferrando","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S","family":"Perkins","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M","family":"Lim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Y","family":"Chu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M S","family":"Cairo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2012,4,13]]},"reference":[{"key":"BFbcj20128_CR1","unstructured":"T lyphoblastic leukaemia\/lymphoma. In: Swerdlow SH, Campo E, Harris NL, Jaffe ES, Pileri SA, Stein H, et al. (eds). WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues. IARC Press: Lyon, 2008, pp. 176\u2013178."},{"key":"BFbcj20128_CR2","unstructured":"Mature T- and NK-cell neoplasms. In: Swerdlow SH, Campo E, Harris NL, Jaffe ES, Pileri SA, Stein H, et al. (eds). WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues. IARC Press: Lyon, 2008, pp. 270\u2013319."},{"key":"BFbcj20128_CR3","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1002\/hon.836","volume":"26","author":"D Rodriguez-Abreu","year":"2008","unstructured":"Rodriguez-Abreu D, Filho VB, Zucca E . Peripheral T-cell lymphomas, unspecified (or not otherwise specified): a review. Hematol Oncol 2008; 26: 8\u201320.","journal-title":"Hematol Oncol"},{"key":"BFbcj20128_CR4","volume-title":"T-Cell Lymphoproliferative Disorders","author":"NK El-Mallawany","year":"2012","unstructured":"El-Mallawany NK, Van Vlierberghe P, Ferrando AA, Lim M, Cairo MS . T-cell malignancies in children and adolescents: state of the clinical and biological science. In: Foss F (ed). T-Cell Lymphoproliferative Disorders. Humana Press: New York, 2012 (in press)."},{"key":"BFbcj20128_CR5","volume-title":"Cancer in Children and Adolescents","author":"MS Cairo","year":"2010","unstructured":"Cairo MS . Non-Hodgkin's lymphoma and lymphoproliferative disorders in children. In: Carroll WL, Finlay J (eds). Cancer in Children and Adolescents. Jones and Bartlett Publishers: Sudbury, MA, 2010."},{"key":"BFbcj20128_CR6","first-page":"2123","volume-title":"Nelson Textbook of Pediatrics","author":"MS Cairo","year":"2007","unstructured":"Cairo MS, Bradley MB . Lymphoma. In: Kliegman RM, Behrman RE, Jenson HB, Stanton BF (eds). Nelson Textbook of Pediatrics, 18th edn. Elsevier: Phildelphia, 2007, pp. 2123\u20132126."},{"key":"BFbcj20128_CR7","first-page":"1962","volume-title":"Cancer Medicine","author":"MS Cairo","year":"2005","unstructured":"Cairo MS, Raetz E, Perkins SL . Non-Hodgkin's lymphoma in children. In: Kufe DW, Bast RC, Hait WN, Hong WK, Pollock R, Weichselbaum RR, et al. (eds). Cancer Medicine, 7th edn. BC Decker Inc.: Hamilton, Ontario, Canada, 2005, pp 1962\u20131976."},{"key":"BFbcj20128_CR8","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1080\/10428190701824551","volume":"49","author":"B Burkhardt","year":"2008","unstructured":"Burkhardt B, Moericke A, Klapper W, Greene F, Salzburg J, Damm-Welk C et al. Pediatric precursor T lymphoblastic leukemia and lymphoblastic lymphoma: differences in the common regions with loss of heterozygosity at chromosome 6q and their prognostic impact. Leuk Lymphoma 2008; 49: 451\u2013461.","journal-title":"Leuk Lymphoma"},{"key":"BFbcj20128_CR9","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1002\/pbc.20550","volume":"47","author":"EA Raetz","year":"2006","unstructured":"Raetz EA, Perkins SL, Bhojwani D, Smock K, Philip M, Carroll WL et al. Gene expression profiling reveals intrinsic differences between T-cell acute lymphoblastic leukemia and T-cell lymphoblastic lymphoma. Pediatr Blood Cancer 2006; 47: 130\u2013140.","journal-title":"Pediatr Blood Cancer"},{"key":"BFbcj20128_CR10","doi-asserted-by":"crossref","first-page":"3363","DOI":"10.1200\/JCO.2008.19.3367","volume":"27","author":"B Burkhardt","year":"2009","unstructured":"Burkhardt B, Reiter A, Landmann E, Lang P, Lassay L, Dickerhoff R et al. Poor outcome for children and adolescents with progressive disease or relapse of lymphoblastic lymphoma: a report from the Berlin-Frankfurt-Muenster group. J Clin Oncol 2009; 27: 3363\u20133369.","journal-title":"J Clin Oncol"},{"key":"BFbcj20128_CR11","first-page":"416","volume":"95","author":"A Reiter","year":"2000","unstructured":"Reiter A, Schrappe M, Ludwig WD, Tiemann M, Parwaresch R, Zimmermann M et al. Intensive ALL-type therapy without local radiotherapy provides a 90% event-free survival for children with T-cell lymphoblastic lymphoma: a BFM group report. Blood 2000; 95: 416\u2013421.","journal-title":"Blood"},{"key":"BFbcj20128_CR12","doi-asserted-by":"crossref","first-page":"2205","DOI":"10.1038\/sj.leu.2401973","volume":"14","author":"M Schrappe","year":"2000","unstructured":"Schrappe M, Reiter A, Zimmermann M, Harbott J, Ludwig WD, Henze G et al. Long-term results of four consecutive trials in childhood ALL performed by the ALL-BFM study group from 1981 to 1995. Berlin-Frankfurt-Munster. Leukemia 2000; 14: 2205\u20132222.","journal-title":"Leukemia"},{"key":"BFbcj20128_CR13","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1002\/(SICI)1096-911X(199802)30:2<101::AID-MPO6>3.0.CO;2-M","volume":"30","author":"H Bertsch","year":"1998","unstructured":"Bertsch H, Rudoler S, Needle MN, Malloy P, Sutton L, Belasco J et al. Emergent\/urgent therapeutic irradiation in pediatric oncology: patterns of presentation, treatment, and outcome. Med Pediatr Oncol 1998; 30: 101\u2013105.","journal-title":"Med Pediatr Oncol"},{"key":"BFbcj20128_CR14","first-page":"722","volume-title":"Principles and Practice of Pediatric Oncology","author":"MP Link","year":"2006","unstructured":"Link MP, Weinstein HJ . Malignant non-hodgkin lymphomas in children. In: Pizzo PA, Poplack DG (eds). Principles and Practice of Pediatric Oncology, 5th edn. Lippincott, Williams and Wilkins: Philadelphia, 2006, pp. 722\u2013747."},{"key":"BFbcj20128_CR15","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1200\/JCO.1989.7.1.92","volume":"7","author":"AT Meadows","year":"1989","unstructured":"Meadows AT, Sposto R, Jenkin RD, Kersey JH, Chilcote RR, Siegel SE et al. Similar efficacy of 6 and 18 months of therapy with four drugs (COMP) for localized non-Hodgkin's lymphoma of children: a report from the Childrens Cancer Study Group. J Clin Oncol 1989; 7: 92\u201399.","journal-title":"J Clin Oncol"},{"key":"BFbcj20128_CR16","doi-asserted-by":"crossref","first-page":"1259","DOI":"10.1056\/NEJM199710303371802","volume":"337","author":"MP Link","year":"1997","unstructured":"Link MP, Shuster JJ, Donaldson SS, Berard CW, Murphy SB . Treatment of children and young adults with early-stage non-Hodgkin's lymphoma. N Engl J Med 1997; 337: 1259\u20131266.","journal-title":"N Engl J Med"},{"key":"BFbcj20128_CR17","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1002\/1097-0142(197601)37:1<123::AID-CNCR2820370119>3.0.CO;2-7","volume":"37","author":"N Wollner","year":"1976","unstructured":"Wollner N, Burchenal JH, Lieberman PH, Exelby P, D\u2019Angio G, Murphy ML . Non-Hodgkin's lymphoma in children. A comparative study of two modalities of therapy. Cancer 1976; 37: 123\u2013134.","journal-title":"Cancer"},{"key":"BFbcj20128_CR18","doi-asserted-by":"crossref","first-page":"953","DOI":"10.1002\/pbc.22162","volume":"53","author":"M Pillon","year":"2009","unstructured":"Pillon M, Piglione M, Garaventa A, Conter V, Giuliano M, Arcamone G et al. Long-term results of AIEOP LNH-92 protocol for the treatment of pediatric lymphoblastic lymphoma: a report of the Italian association of pediatric hematology and oncology. Pediatr Blood Cancer 2009; 53: 953\u2013959.","journal-title":"Pediatr Blood Cancer"},{"key":"BFbcj20128_CR19","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1200\/JCO.2005.02.2707","volume":"24","author":"B Burkhardt","year":"2006","unstructured":"Burkhardt B, Woessmann W, Zimmermann M, Kontny U, Vormoor J, Doerffel W et al. Impact of cranial radiotherapy on central nervous system prophylaxis in children and adolescents with central nervous system-negative stage III or IV lymphoblastic lymphoma. J Clin Oncol 2006; 24: 491\u2013499.","journal-title":"J Clin Oncol"},{"key":"BFbcj20128_CR20","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1111\/j.1365-2141.2008.07320.x","volume":"143","author":"M Abromowitch","year":"2008","unstructured":"Abromowitch M, Sposto R, Perkins S, Zwick D, Siegel S, Finlay J et al. Shortened intensified multi-agent chemotherapy and non-cross resistant maintenance therapy for advanced lymphoblastic lymphoma in children and adolescents: report from the Children's Oncology Group. Br J Haematol 2008; 143: 261\u2013267.","journal-title":"Br J Haematol"},{"key":"BFbcj20128_CR21","first-page":"33","volume":"3","author":"M Abromowitch","year":"2009","unstructured":"Abromowitch M, Termuhlen A, Lynch J, Chang M, Perkins SL, Gross T et al. High-dose methotrexate and early intensification of therapy do not improve 3 year EFS in children and adolescents with disseminated lymphoblastic lymphoma. Results of the randomized arms of COG A5971. Hematol Meeting Rep 2009, (abstract); 3: 33.","journal-title":"Hematol Meeting Rep"},{"key":"BFbcj20128_CR22","doi-asserted-by":"crossref","first-page":"840","DOI":"10.1016\/j.ejca.2008.02.011","volume":"44","author":"A Uyttebroeck","year":"2008","unstructured":"Uyttebroeck A, Suciu S, Laureys G, Robert A, Pacquement H, Ferster A et al. Treatment of childhood T-cell lymphoblastic lymphoma according to the strategy for acute lymphoblastic leukaemia, without radiotherapy: long term results of the EORTC CLG 58881 trial. Eur J Cancer 2008; 44: 840\u2013846.","journal-title":"Eur J Cancer"},{"key":"BFbcj20128_CR23","doi-asserted-by":"crossref","first-page":"1127","DOI":"10.1038\/leu.2008.400","volume":"23","author":"JT Sandlund","year":"2009","unstructured":"Sandlund JT, Pui CH, Zhou Y, Behm FG, Onciu M, Razzouk BI et al. Effective treatment of advanced-stage childhood lymphoblastic lymphoma without prophylactic cranial irradiation: results of St Jude NHL13 study. Leukemia 2009; 23: 1127\u20131130.","journal-title":"Leukemia"},{"key":"BFbcj20128_CR24","doi-asserted-by":"crossref","first-page":"1024","DOI":"10.1200\/JCO.1993.11.6.1024","volume":"11","author":"JR Anderson","year":"1993","unstructured":"Anderson JR, Jenkin RD, Wilson JF, Kjeldsberg CR, Sposto R, Chilcote RR et al. Long-term follow-up of patients treated with COMP or LSA2L2 therapy for childhood non-Hodgkin's lymphoma: a report of CCG-551 from the Childrens Cancer Group. J Clin Oncol 1993; 11: 1024\u20131032.","journal-title":"J Clin Oncol"},{"key":"BFbcj20128_CR25","doi-asserted-by":"crossref","first-page":"979","DOI":"10.1200\/JCO.1984.2.9.979","volume":"2","author":"O Hartmann","year":"1984","unstructured":"Hartmann O, Pein F, Beaujean F, Kalifa C, Patte C, Parmentier C et al. High-dose polychemotherapy with autologous bone marrow transplantation in children with relapsed lymphomas. J Clin Oncol 1984; 2: 979\u2013985.","journal-title":"J Clin Oncol"},{"key":"BFbcj20128_CR26","doi-asserted-by":"crossref","first-page":"588","DOI":"10.1200\/JCO.1995.13.3.588","volume":"13","author":"W Mills","year":"1995","unstructured":"Mills W, Chopra R, McMillan A, Pearce R, Linch DC, Goldstone AH . BEAM chemotherapy and autologous bone marrow transplantation for patients with relapsed or refractory non-Hodgkin's lymphoma. J Clin Oncol 1995; 13: 588\u2013595.","journal-title":"J Clin Oncol"},{"key":"BFbcj20128_CR27","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1007\/s00277-006-0169-2","volume":"85","author":"SC Won","year":"2006","unstructured":"Won SC, Han JW, Kwon SY, Shin HY, Ahn HS, Hwang TJ et al. Autologous peripheral blood stem cell transplantation in children with non-Hodgkin's lymphoma: a report from the Korean Society of Pediatric Hematology-Oncology. Ann Hematol 2006; 85: 787\u2013794.","journal-title":"Ann Hematol"},{"key":"BFbcj20128_CR28","doi-asserted-by":"crossref","first-page":"953","DOI":"10.1038\/sj.bmt.1701002","volume":"20","author":"S Kleiner","year":"1997","unstructured":"Kleiner S, Kirsch A, Schwaner I, Kingreen D, Schwella N, Huhn D et al. High-dose chemotherapy with carboplatin, etoposide and ifosfamide followed by autologous stem cell rescue in patients with relapsed or refractory malignant lymphomas: a phase I\/II study. Bone Marrow Transplant 1997; 20: 953\u2013959.","journal-title":"Bone Marrow Transplant"},{"key":"BFbcj20128_CR29","doi-asserted-by":"crossref","first-page":"2390","DOI":"10.1200\/JCO.2001.19.9.2390","volume":"19","author":"NL Kobrinsky","year":"2001","unstructured":"Kobrinsky NL, Sposto R, Shah NR, Anderson JR, DeLaat C, Morse M et al. Outcomes of treatment of children and adolescents with recurrent non-Hodgkin's lymphoma and Hodgkin's disease with dexamethasone, etoposide, cisplatin, cytarabine, and l-asparaginase, maintenance chemotherapy, and transplantation: Children's Cancer Group Study CCG-5912. J Clin Oncol 2001; 19: 2390\u20132396.","journal-title":"J Clin Oncol"},{"key":"BFbcj20128_CR30","first-page":"353","volume":"15","author":"E Bureo","year":"1995","unstructured":"Bureo E, Ortega JJ, Munoz A, Cubells J, Madero L, Verdaguer A et al. Bone marrow transplantation in 46 pediatric patients with non-Hodgkin's lymphoma. Spanish Working Party for Bone Marrow Transplantation in Children. Bone Marrow Transplant 1995; 15: 353\u2013359.","journal-title":"Bone Marrow Transplant"},{"key":"BFbcj20128_CR31","doi-asserted-by":"crossref","first-page":"2476","DOI":"10.1182\/blood-2002-05-1483","volume":"101","author":"JE Levine","year":"2003","unstructured":"Levine JE, Harris RE, Loberiza Jr FR, Armitage JO, Vose JM, Van Besien K et al. A comparison of allogeneic and autologous bone marrow transplantation for lymphoblastic lymphoma. Blood 2003; 101: 2476\u20132482.","journal-title":"Blood"},{"key":"BFbcj20128_CR32","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1016\/j.bbmt.2009.09.021","volume":"16","author":"TG Gross","year":"2010","unstructured":"Gross TG, Hale GA, He W, Camitta BM, Sanders JE, Cairo MS et al. Hematopoietic stem cell transplantation for refractory or recurrent non-Hodgkin lymphoma in children and adolescents. Biol Blood Marrow Transplant 2010; 16: 223\u2013230.","journal-title":"Biol Blood Marrow Transplant"},{"key":"BFbcj20128_CR33","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1002\/pbc.21941","volume":"52","author":"T Mitsui","year":"2009","unstructured":"Mitsui T, Mori T, Fujita N, Inada H, Horibe K, Tsurusawa M . Retrospective analysis of relapsed or primary refractory childhood lymphoblastic lymphoma in Japan. Pediatr Blood Cancer 2009; 52: 591\u2013595.","journal-title":"Pediatr Blood Cancer"},{"key":"BFbcj20128_CR34","doi-asserted-by":"crossref","first-page":"3376","DOI":"10.1200\/JCO.2005.03.426","volume":"23","author":"SL Berg","year":"2005","unstructured":"Berg SL, Blaney SM, Devidas M, Lampkin TA, Murgo A, Bernstein M et al. Phase II study of nelarabine (compound 506U78) in children and young adults with refractory T-cell malignancies: a report from the Children's Oncology Group. J Clin Oncol 2005; 23: 3376\u20133382.","journal-title":"J Clin Oncol"},{"key":"BFbcj20128_CR35","doi-asserted-by":"crossref","first-page":"2392","DOI":"10.1182\/blood-2006-03-007468","volume":"108","author":"K Balakrishnan","year":"2006","unstructured":"Balakrishnan K, Nimmanapalli R, Ravandi F, Keating MJ, Gandhi V . Forodesine, an inhibitor of purine nucleoside phosphorylase, induces apoptosis in chronic lymphocytic leukemia cells. Blood 2006; 108: 2392\u20132398.","journal-title":"Blood"},{"key":"BFbcj20128_CR36","doi-asserted-by":"crossref","first-page":"1376","DOI":"10.1182\/blood-2005-01-0272","volume":"106","author":"C Haioun","year":"2005","unstructured":"Haioun C, Itti E, Rahmouni A, Brice P, Rain JD, Belhadj K et al. [18F]fluoro-2-deoxy-D-glucose positron emission tomography (FDG-PET) in aggressive lymphoma: an early prognostic tool for predicting patient outcome. Blood 2005; 106: 1376\u20131381.","journal-title":"Blood"},{"key":"BFbcj20128_CR37","first-page":"37","volume":"3","author":"F Lovisa","year":"2009","unstructured":"Lovisa F, Mussolin L, Corral L, Pillon M, Cazzaniga G, Biondi A et al. TCR-based RQ-PCR assay for MDD and MRD assessment in T-cell lymphoblastic lymphoma of childhood. Hematol Meeting Rep 2009, (abstract); 3: 37.","journal-title":"Hematol Meeting Rep"},{"key":"BFbcj20128_CR38","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1002\/pbc.21823","volume":"52","author":"B Stark","year":"2009","unstructured":"Stark B, Avigad S, Luria D, Manor S, Reshef-Ronen T, Avrahami G et al. Bone marrow minimal disseminated disease (MDD) and minimal residual disease (MRD) in childhood T-cell lymphoblastic lymphoma stage III, detected by flow cytometry (FC) and real-time quantitative polymerase chain reaction (RQ-PCR). Pediatr Blood Cancer 2009; 52: 20\u201325.","journal-title":"Pediatr Blood Cancer"},{"key":"BFbcj20128_CR39","doi-asserted-by":"crossref","first-page":"3533","DOI":"10.1200\/JCO.2008.21.1318","volume":"27","author":"E Coustan-Smith","year":"2009","unstructured":"Coustan-Smith E, Sandlund JT, Perkins SL, Chen H, Chang M, Abromowitch M et al. Minimal disseminated disease in childhood T-cell lymphoblastic lymphoma: a report from the children's oncology group. J Clin Oncol 2009; 27: 3533\u20133539.","journal-title":"J Clin Oncol"},{"key":"BFbcj20128_CR40","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1016\/S1470-2045(08)70314-0","volume":"10","author":"E Coustan-Smith","year":"2009","unstructured":"Coustan-Smith E, Mullighan CG, Onciu M, Behm FG, Raimondi SC, Pei D et al. Early T-cell precursor leukaemia: a subtype of very high-risk acute lymphoblastic leukaemia. Lancet Oncol 2009; 10: 147\u2013156.","journal-title":"Lancet Oncol"},{"key":"BFbcj20128_CR41","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1038\/nri2304","volume":"8","author":"I Aifantis","year":"2008","unstructured":"Aifantis I, Raetz E, Buonamici S . Molecular pathogenesis of T-cell leukaemia and lymphoma. Nat Rev Immunol 2008; 8: 380\u2013390.","journal-title":"Nat Rev Immunol"},{"key":"BFbcj20128_CR42","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1097\/00062752-200107000-00001","volume":"8","author":"DG Gilliland","year":"2001","unstructured":"Gilliland DG . Hematologic malignancies. Curr Opin Hematol 2001; 8: 189\u2013191.","journal-title":"Curr Opin Hematol"},{"key":"BFbcj20128_CR43","first-page":"1116","volume":"90","author":"K De Keersmaecker","year":"2005","unstructured":"De Keersmaecker K, Marynen P, Cools J . Genetic insights in the pathogenesis of T-cell acute lymphoblastic leukemia. Haematologica 2005; 90: 1116\u20131127.","journal-title":"Haematologica"},{"key":"BFbcj20128_CR44","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1111\/j.1365-2141.2008.07314.x","volume":"143","author":"P Van Vlierberghe","year":"2008","unstructured":"Van Vlierberghe P, Pieters R, Beverloo HB, Meijerink JP . Molecular-genetic insights in paediatric T-cell acute lymphoblastic leukaemia. Br J Haematol 2008; 143: 153\u2013168.","journal-title":"Br J Haematol"},{"key":"BFbcj20128_CR45","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1111\/j.1365-2141.2009.08006.x","volume":"149","author":"B Burkhardt","year":"2010","unstructured":"Burkhardt B . Paediatric lymphoblastic T-cell leukaemia and lymphoma: one or two diseases? Br J Haematol 2010; 149: 653\u2013668.","journal-title":"Br J Haematol"},{"key":"BFbcj20128_CR46","doi-asserted-by":"crossref","first-page":"158","DOI":"10.3324\/haematol.2009.007526","volume":"95","author":"D Krieger","year":"2010","unstructured":"Krieger D, Moericke A, Oschlies I, Zimmermann M, Schrappe M, Reiter A et al. Frequency and clinical relevance of DNA microsatellite alterations of the CDKN2A\/B, ATM and p53 gene loci: a comparison between pediatric precursor T-cell lymphoblastic lymphoma and T-cell lymphoblastic leukemia. Haematologica 2010; 95: 158\u2013162.","journal-title":"Haematologica"},{"key":"BFbcj20128_CR47","doi-asserted-by":"crossref","first-page":"6838","DOI":"10.1038\/sj.onc.1210766","volume":"26","author":"J O\u2019Neil","year":"2007","unstructured":"O\u2019Neil J, Look AT . Mechanisms of transcription factor deregulation in lymphoid cell transformation. Oncogene 2007; 26: 6838\u20136849.","journal-title":"Oncogene"},{"key":"BFbcj20128_CR48","doi-asserted-by":"crossref","first-page":"1496","DOI":"10.1038\/sj.leu.2404302","volume":"20","author":"C Graux","year":"2006","unstructured":"Graux C, Cools J, Michaux L, Vandenberghe P, Hagemeijer A . Cytogenetics and molecular genetics of T-cell acute lymphoblastic leukemia: from thymocyte to lymphoblast. Leukemia 2006; 20: 1496\u20131510.","journal-title":"Leukemia"},{"key":"BFbcj20128_CR49","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1146\/annurev.pathol.4.110807.092227","volume":"4","author":"MA Teitell","year":"2009","unstructured":"Teitell MA, Pandolfi PP . Molecular genetics of acute lymphoblastic leukemia. Annu Rev Pathol 2009; 4: 175\u2013198.","journal-title":"Annu Rev Pathol"},{"key":"BFbcj20128_CR50","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1016\/S0037-1963(03)00195-1","volume":"40","author":"AA Ferrando","year":"2003","unstructured":"Ferrando AA, Look AT . Gene expression profiling in T-cell acute lymphoblastic leukemia. Semin Hematol 2003; 40: 274\u2013280.","journal-title":"Semin Hematol"},{"key":"BFbcj20128_CR51","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/S1535-6108(02)00018-1","volume":"1","author":"AA Ferrando","year":"2002","unstructured":"Ferrando AA, Neuberg DS, Staunton J, Loh ML, Huard C, Raimondi SC et al. Gene expression signatures define novel oncogenic pathways in T cell acute lymphoblastic leukemia. Cancer Cell 2002; 1: 75\u201387.","journal-title":"Cancer Cell"},{"key":"BFbcj20128_CR52","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1182\/blood-2004-10-3900","volume":"106","author":"J Soulier","year":"2005","unstructured":"Soulier J, Clappier E, Cayuela JM, Regnault A, Garcia-Peydro M, Dombret H et al. HOXA genes are included in genetic and biologic networks defining human acute T-cell leukemia (T-ALL). Blood 2005; 106: 274\u2013286.","journal-title":"Blood"},{"key":"BFbcj20128_CR53","doi-asserted-by":"crossref","first-page":"4038","DOI":"10.1182\/blood.V84.12.4038.bloodjournal84124038","volume":"84","author":"J Hebert","year":"1994","unstructured":"Hebert J, Cayuela JM, Berkeley J, Sigaux F . Candidate tumor-suppressor genes MTS1 (p16INK4A) and MTS2 (p15INK4B) display frequent homozygous deletions in primary cells from T- but not from B-cell lineage acute lymphoblastic leukemias. Blood 1994; 84: 4038\u20134044.","journal-title":"Blood"},{"key":"BFbcj20128_CR54","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1126\/science.1102160","volume":"306","author":"AP Weng","year":"2004","unstructured":"Weng AP, Ferrando AA, Lee W, Morris JPt, Silverman LB, Sanchez-Irizarry C et al. Activating mutations of NOTCH1 in human T cell acute lymphoblastic leukemia. Science 2004; 306: 269\u2013271.","journal-title":"Science"},{"key":"BFbcj20128_CR55","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1111\/j.1365-2141.1989.tb07648.x","volume":"72","author":"M Bar-Eli","year":"1989","unstructured":"Bar-Eli M, Ahuja H, Foti A, Cline MJ . N-RAS mutations in T-cell acute lymphocytic leukaemia: analysis by direct sequencing detects a novel mutation. Br J Haematol 1989; 72: 36\u201339.","journal-title":"Br J Haematol"},{"key":"BFbcj20128_CR56","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1084\/jem.20072182","volume":"205","author":"E Flex","year":"2008","unstructured":"Flex E, Petrangeli V, Stella L, Chiaretti S, Hornakova T, Knoops L et al. Somatically acquired JAK1 mutations in adult acute lymphoblastic leukemia. J Exp Med 2008; 205: 751\u2013758.","journal-title":"J Exp Med"},{"key":"BFbcj20128_CR57","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1182\/blood-2004-01-0168","volume":"104","author":"E Paietta","year":"2004","unstructured":"Paietta E, Ferrando AA, Neuberg D, Bennett JM, Racevskis J, Lazarus H et al. Activating FLT3 mutations in CD117\/KIT(+) T-cell acute lymphoblastic leukemias. Blood 2004; 104: 558\u2013560.","journal-title":"Blood"},{"key":"BFbcj20128_CR58","doi-asserted-by":"crossref","first-page":"4322","DOI":"10.1182\/blood-2007-06-095075","volume":"111","author":"BV Balgobind","year":"2008","unstructured":"Balgobind BV, Van Vlierberghe P, van den Ouweland AM, Beverloo HB, Terlouw-Kromosoeto JN, van Wering ER et al. Leukemia-associated NF1 inactivation in patients with pediatric T-ALL and AML lacking evidence for neurofibromatosis. Blood 2008; 111: 4322\u20134328.","journal-title":"Blood"},{"key":"BFbcj20128_CR59","doi-asserted-by":"crossref","first-page":"1203","DOI":"10.1038\/nm1636","volume":"13","author":"T Palomero","year":"2007","unstructured":"Palomero T, Sulis ML, Cortina M, Real PJ, Barnes K, Ciofani M et al. Mutational loss of PTEN induces resistance to NOTCH1 inhibition in T-cell leukemia. Nat Med 2007; 13: 1203\u20131210.","journal-title":"Nat Med"},{"key":"BFbcj20128_CR60","doi-asserted-by":"crossref","first-page":"1038","DOI":"10.1182\/blood-2008-12-192039","volume":"114","author":"V Tosello","year":"2009","unstructured":"Tosello V, Mansour MR, Barnes K, Paganin M, Sulis ML, Jenkinson S et al. WT1 mutations in T-ALL. Blood 2009; 114: 1038\u20131045.","journal-title":"Blood"},{"key":"BFbcj20128_CR61","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1038\/ni1216","volume":"6","author":"A Sambandam","year":"2005","unstructured":"Sambandam A, Maillard I, Zediak VP, Xu L, Gerstein RM, Aster JC et al. Notch signaling controls the generation and differentiation of early T lineage progenitors. Nat Immunol 2005; 6: 663\u2013670.","journal-title":"Nat Immunol"},{"key":"BFbcj20128_CR62","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1016\/j.coi.2004.01.002","volume":"16","author":"F Radtke","year":"2004","unstructured":"Radtke F, Wilson A, MacDonald HR . Notch signaling in T- and B-cell development. Curr Opin Immunol 2004; 16: 174\u2013179.","journal-title":"Curr Opin Immunol"},{"key":"BFbcj20128_CR63","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1038\/ni1045","volume":"5","author":"F Radtke","year":"2004","unstructured":"Radtke F, Wilson A, Mancini SJ, MacDonald HR . Notch regulation of lymphocyte development and function. Nat Immunol 2004; 5: 247\u2013253.","journal-title":"Nat Immunol"},{"key":"BFbcj20128_CR64","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1016\/0092-8674(91)90111-B","volume":"66","author":"LW Ellisen","year":"1991","unstructured":"Ellisen LW, Bird J, West DC, Soreng AL, Reynolds TC, Smith SD et al. TAN-1, the human homolog of the Drosophila notch gene, is broken by chromosomal translocations in T lymphoblastic neoplasms. Cell 1991; 66: 649\u2013661.","journal-title":"Cell"},{"key":"BFbcj20128_CR65","doi-asserted-by":"crossref","first-page":"2283","DOI":"10.1084\/jem.183.5.2283","volume":"183","author":"WS Pear","year":"1996","unstructured":"Pear WS, Aster JC, Scott ML, Hasserjian RP, Soffer B, Sklar J et al. Exclusive development of T cell neoplasms in mice transplanted with bone marrow expressing activated Notch alleles. J Exp Med 1996; 183: 2283\u20132291.","journal-title":"J Exp Med"},{"key":"BFbcj20128_CR66","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1038\/sj.leu.2404546","volume":"21","author":"J Chen","year":"2007","unstructured":"Chen J, Jette C, Kanki JP, Aster JC, Look AT, Griffin JD . NOTCH1-induced T-cell leukemia in transgenic zebrafish. Leukemia 2007; 21: 462\u2013471.","journal-title":"Leukemia"},{"key":"BFbcj20128_CR67","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1016\/j.chembiol.2006.12.010","volume":"14","author":"HD Lewis","year":"2007","unstructured":"Lewis HD, Leveridge M, Strack PR, Haldon CD, O\u2019Neil J, Kim H et al. Apoptosis in T cell acute lymphoblastic leukemia cells after cell cycle arrest induced by pharmacological inhibition of notch signaling. Chem Biol 2007; 14: 209\u2013219.","journal-title":"Chem Biol"},{"key":"BFbcj20128_CR68","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1038\/nm.1900","volume":"15","author":"PJ Real","year":"2009","unstructured":"Real PJ, Tosello V, Palomero T, Castillo M, Hernando E, de Stanchina E et al. Gamma-secretase inhibitors reverse glucocorticoid resistance in T cell acute lymphoblastic leukemia. Nat Med 2009; 15: 50\u201358.","journal-title":"Nat Med"},{"key":"BFbcj20128_CR69","doi-asserted-by":"crossref","first-page":"965","DOI":"10.4161\/cc.7.8.5753","volume":"7","author":"T Palomero","year":"2008","unstructured":"Palomero T, Dominguez M, Ferrando AA . The role of the PTEN\/AKT pathway in NOTCH1-induced leukemia. Cell Cycle 2008; 7: 965\u2013970.","journal-title":"Cell Cycle"},{"key":"BFbcj20128_CR70","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1182\/blood-2006-08-039883","volume":"110","author":"SM Chan","year":"2007","unstructured":"Chan SM, Weng AP, Tibshirani R, Aster JC, Utz PJ . Notch signals positively regulate activity of the mTOR pathway in T-cell acute lymphoblastic leukemia. Blood 2007; 110: 278\u2013286.","journal-title":"Blood"},{"key":"BFbcj20128_CR71","doi-asserted-by":"crossref","first-page":"6172","DOI":"10.1182\/blood-2008-02-136762","volume":"113","author":"K Cullion","year":"2009","unstructured":"Cullion K, Draheim KM, Hermance N, Tammam J, Sharma VM, Ware C et al. Targeting the Notch1 and mTOR pathways in a mouse T-ALL model. Blood 2009; 113: 6172\u20136181.","journal-title":"Blood"},{"key":"BFbcj20128_CR72","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1038\/nm1524","volume":"13","author":"T Vilimas","year":"2007","unstructured":"Vilimas T, Mascarenhas J, Palomero T, Mandal M, Buonamici S, Meng F et al. Targeting the NF-kappaB signaling pathway in Notch1-induced T-cell leukemia. Nat Med 2007; 13: 70\u201377.","journal-title":"Nat Med"},{"key":"BFbcj20128_CR73","doi-asserted-by":"crossref","first-page":"1000","DOI":"10.1038\/nature08020","volume":"459","author":"S Buonamici","year":"2009","unstructured":"Buonamici S, Trimarchi T, Ruocco MG, Reavie L, Cathelin S, Mar BG et al. CCR7 signalling as an essential regulator of CNS infiltration in T-cell leukaemia. Nature 2009; 459: 1000\u20131004.","journal-title":"Nature"},{"key":"BFbcj20128_CR74","doi-asserted-by":"crossref","first-page":"6068","DOI":"10.1073\/pnas.0408708102","volume":"102","author":"DM Langenau","year":"2005","unstructured":"Langenau DM, Feng H, Berghmans S, Kanki JP, Kutok JL, Look AT . Cre\/lox-regulated transgenic zebrafish model with conditional myc-induced T cell acute lymphoblastic leukemia. Proc Natl Acad Sci USA 2005; 102: 6068\u20136073.","journal-title":"Proc Natl Acad Sci USA"},{"key":"BFbcj20128_CR75","doi-asserted-by":"crossref","first-page":"1825","DOI":"10.1038\/leu.2009.116","volume":"23","author":"JK Frazer","year":"2009","unstructured":"Frazer JK, Meeker ND, Rudner L, Bradley DF, Smith AC, Demarest B et al. Heritable T-cell malignancy models established in a zebrafish phenotypic screen. Leukemia 2009; 23: 1825\u20131835.","journal-title":"Leukemia"},{"key":"BFbcj20128_CR76","doi-asserted-by":"crossref","first-page":"848","DOI":"10.1182\/blood.V66.4.848.848","volume":"66","author":"H Stein","year":"1985","unstructured":"Stein H, Mason DY, Gerdes J, O\u2019Connor N, Wainscoat J, Pallesen G et al. The expression of the Hodgkin's disease associated antigen Ki-1 in reactive and neoplastic lymphoid tissue: evidence that Reed-Sternberg cells and histiocytic malignancies are derived from activated lymphoid cells. Blood 1985; 66: 848\u2013858.","journal-title":"Blood"},{"key":"BFbcj20128_CR77","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1038\/nrc2291","volume":"8","author":"R Chiarle","year":"2008","unstructured":"Chiarle R, Voena C, Ambrogio C, Piva R, Inghirami G . The anaplastic lymphoma kinase in the pathogenesis of cancer. Nat Rev Cancer 2008; 8: 11\u201323.","journal-title":"Nat Rev Cancer"},{"key":"BFbcj20128_CR78","unstructured":"World Health Organization. Tumours of haematopoietic and lymphoid tissues. In: Jaffe E, Harris N, Stein H, Vardiman J (eds). World Health Organization Classification of Tumors. IARC Press: Washington, DC, 2000."},{"key":"BFbcj20128_CR79","doi-asserted-by":"crossref","first-page":"3681","DOI":"10.1182\/blood.V96.12.3681","volume":"96","author":"H Stein","year":"2000","unstructured":"Stein H, Foss HD, Durkop H, Marafioti T, Delsol G, Pulford K et al. CD30(+) anaplastic large cell lymphoma: a review of its histopathologic, genetic, and clinical features. Blood 2000; 96: 3681\u20133695.","journal-title":"Blood"},{"key":"BFbcj20128_CR80","doi-asserted-by":"crossref","first-page":"5623","DOI":"10.1038\/sj.onc.1204594","volume":"20","author":"J Duyster","year":"2001","unstructured":"Duyster J, Bai RY, Morris SW . Translocations involving anaplastic lymphoma kinase (ALK). Oncogene 2001; 20: 5623\u20135637.","journal-title":"Oncogene"},{"key":"BFbcj20128_CR81","doi-asserted-by":"crossref","first-page":"2156","DOI":"10.1182\/blood-2006-06-028969","volume":"109","author":"L Lamant","year":"2007","unstructured":"Lamant L, de Reynies A, Duplantier MM, Rickman DS, Sabourdy F, Giuriato S et al. Gene-expression profiling of systemic anaplastic large-cell lymphoma reveals differences based on ALK status and two distinct morphologic ALK+ subtypes. Blood 2007; 109: 2156\u20132164.","journal-title":"Blood"},{"key":"BFbcj20128_CR82","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1111\/j.1365-2141.2007.06924.x","volume":"140","author":"I Salaverria","year":"2008","unstructured":"Salaverria I, Bea S, Lopez-Guillermo A, Lespinet V, Pinyol M, Burkhardt B et al. Genomic profiling reveals different genetic aberrations in systemic ALK-positive and ALK-negative anaplastic large cell lymphomas. Br J Haematol 2008; 140: 516\u2013526.","journal-title":"Br J Haematol"},{"key":"BFbcj20128_CR83","doi-asserted-by":"crossref","first-page":"2076","DOI":"10.1182\/blood.V91.6.2076","volume":"91","author":"D Benharroch","year":"1998","unstructured":"Benharroch D, Meguerian-Bedoyan Z, Lamant L, Amin C, Brugieres L, Terrier-Lacombe MJ et al. ALK-positive lymphoma: a single disease with a broad spectrum of morphology. Blood 1998; 91: 2076\u20132084.","journal-title":"Blood"},{"key":"BFbcj20128_CR84","doi-asserted-by":"crossref","first-page":"1361","DOI":"10.1182\/blood.V84.5.1361.1361","volume":"84","author":"NL Harris","year":"1994","unstructured":"Harris NL, Jaffe ES, Stein H, Banks PM, Chan JK, Cleary ML et al. A revised European-American classification of lymphoid neoplasms: a proposal from the International Lymphoma Study Group. Blood 1994; 84: 1361\u20131392.","journal-title":"Blood"},{"key":"BFbcj20128_CR85","first-page":"2697","volume":"93","author":"B Falini","year":"1999","unstructured":"Falini B, Pileri S, Zinzani PL, Carbone A, Zagonel V, Wolf-Peeters C et al. ALK+ lymphoma: clinico-pathological findings and outcome. Blood 1999; 93: 2697\u20132706.","journal-title":"Blood"},{"key":"BFbcj20128_CR86","doi-asserted-by":"crossref","first-page":"1560","DOI":"10.1182\/blood-2007-07-100958","volume":"111","author":"MC Le Deley","year":"2008","unstructured":"Le Deley MC, Reiter A, Williams D, Delsol G, Oschlies I, McCarthy K et al. Prognostic factors in childhood anaplastic large cell lymphoma: results of a large European intergroup study. Blood 2008; 111: 1560\u20131566.","journal-title":"Blood"},{"key":"BFbcj20128_CR87","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1038\/modpathol.3880289","volume":"14","author":"ES Jaffe","year":"2001","unstructured":"Jaffe ES . Anaplastic large cell lymphoma: the shifting sands of diagnostic hematopathology. Mod Pathol 2001; 14: 219\u2013228.","journal-title":"Mod Pathol"},{"key":"BFbcj20128_CR88","doi-asserted-by":"crossref","first-page":"3915","DOI":"10.1200\/JCO.2007.11.0700","volume":"25","author":"J Salzburg","year":"2007","unstructured":"Salzburg J, Burkhardt B, Zimmermann M, Wachowski O, Woessmann W, Oschlies I et al. Prevalence, clinical pattern, and outcome of CNS involvement in childhood and adolescent non-Hodgkin's lymphoma differ by non-Hodgkin's lymphoma subtype: a Berlin-Frankfurt-Munster Group Report. J Clin Oncol 2007; 25: 3915\u20133922.","journal-title":"J Clin Oncol"},{"key":"BFbcj20128_CR89","doi-asserted-by":"crossref","first-page":"3699","DOI":"10.1182\/blood.V97.12.3699","volume":"97","author":"K Seidemann","year":"2001","unstructured":"Seidemann K, Tiemann M, Schrappe M, Yakisan E, Simonitsch I, Janka-Schaub G et al. Short-pulse B-non-Hodgkin lymphoma-type chemotherapy is efficacious treatment for pediatric anaplastic large cell lymphoma: a report of the Berlin-Frankfurt-Munster Group Trial NHL-BFM 90. Blood 2001; 97: 3699\u20133706.","journal-title":"Blood"},{"key":"BFbcj20128_CR90","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1200\/JCO.1994.12.5.895","volume":"12","author":"JT Sandlund","year":"1994","unstructured":"Sandlund JT, Pui CH, Santana VM, Mahmoud H, Roberts WM, Morris S et al. Clinical features and treatment outcome for children with CD30+ large-cell non-Hodgkin's lymphoma. J Clin Oncol 1994; 12: 895\u2013898.","journal-title":"J Clin Oncol"},{"key":"BFbcj20128_CR91","first-page":"3591","volume":"92","author":"L Brugieres","year":"1998","unstructured":"Brugieres L, Deley MC, Pacquement H, Meguerian-Bedoyan Z, Terrier-Lacombe MJ, Robert A et al. CD30(+) anaplastic large-cell lymphoma in children: analysis of 82 patients enrolled in two consecutive studies of the French Society of Pediatric Oncology. Blood 1998; 92: 3591\u20133598.","journal-title":"Blood"},{"key":"BFbcj20128_CR92","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1200\/JCO.2005.11.075","volume":"23","author":"JH Laver","year":"2005","unstructured":"Laver JH, Kraveka JM, Hutchison RE, Chang M, Kepner J, Schwenn M et al. Advanced-stage large-cell lymphoma in children and adolescents: results of a randomized trial incorporating intermediate-dose methotrexate and high-dose cytarabine in the maintenance phase of the APO regimen: a Pediatric Oncology Group phase III trial. J Clin Oncol 2005; 23: 541\u2013547.","journal-title":"J Clin Oncol"},{"key":"BFbcj20128_CR93","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1002\/pbc.21817","volume":"52","author":"EJ Lowe","year":"2009","unstructured":"Lowe EJ, Sposto R, Perkins SL, Gross TG, Finlay J, Zwick D et al. Intensive chemotherapy for systemic anaplastic large cell lymphoma in children and adolescents: final results of Children's Cancer Group Study 5941. Pediatr Blood Cancer 2009; 52: 335\u2013339.","journal-title":"Pediatr Blood Cancer"},{"key":"BFbcj20128_CR94","doi-asserted-by":"crossref","first-page":"2133","DOI":"10.1002\/cncr.21438","volume":"104","author":"A Rosolen","year":"2005","unstructured":"Rosolen A, Pillon M, Garaventa A, Burnelli R, d\u2019Amore ES, Giuliano M et al. Anaplastic large cell lymphoma treated with a leukemia-like therapy: report of the Italian Association of Pediatric Hematology and Oncology (AIEOP) LNH-92 protocol. Cancer 2005; 104: 2133\u20132140.","journal-title":"Cancer"},{"key":"BFbcj20128_CR95","doi-asserted-by":"crossref","first-page":"812","DOI":"10.1046\/j.1365-2141.2002.03482.x","volume":"117","author":"DM Williams","year":"2002","unstructured":"Williams DM, Hobson R, Imeson J, Gerrard M, McCarthy K, Pinkerton CR . Anaplastic large cell lymphoma in childhood: analysis of 72 patients treated on The United Kingdom Children's Cancer Study Group chemotherapy regimens. Br J Haematol 2002; 117: 812\u2013820.","journal-title":"Br J Haematol"},{"key":"BFbcj20128_CR96","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1023\/A:1008352726155","volume":"11","author":"L Brugieres","year":"2000","unstructured":"Brugieres L, Quartier P, Le Deley MC, Pacquement H, Perel Y, Bergeron C et al. Relapses of childhood anaplastic large-cell lymphoma: treatment results in a series of 41 children--a report from the French Society of Pediatric Oncology. Ann Oncol 2000; 11: 53\u201358.","journal-title":"Ann Oncol"},{"key":"BFbcj20128_CR97","first-page":"41","volume":"3","author":"JM Kraveka","year":"2009","unstructured":"Kraveka JM, Weitzman S, Smith L, Lynch JC, Chang M, Kinney M et al. Advanced-stage anaplastic large-cell lymphoma in children and adolescents: results of ANHL0131, a randomized phase III trial with standard APO (doxorubicin, prednisone, vincristine) versus consolidation with a regimen including vinblastine: a report from the Children's Oncology Group. Hematol Meeting Rep 2009, (abstract); 3: 41.","journal-title":"Hematol Meeting Rep"},{"key":"BFbcj20128_CR98","doi-asserted-by":"crossref","first-page":"897","DOI":"10.1200\/JCO.2008.18.1487","volume":"27","author":"L Brugieres","year":"2009","unstructured":"Brugieres L, Le Deley MC, Rosolen A, Williams D, Horibe K, Wrobel G et al. Impact of the methotrexate administration dose on the need for intrathecal treatment in children and adolescents with anaplastic large-cell lymphoma: results of a randomized trial of the EICNHL Group. J Clin Oncol 2009; 27: 897\u2013903.","journal-title":"J Clin Oncol"},{"key":"BFbcj20128_CR99","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1002\/mpo.1176","volume":"37","author":"M Massimino","year":"2001","unstructured":"Massimino M, Spreafico F, Luksch R, Giardini R . Prognostic significance of p80 and visceral involvement in childhood CD30 anaplastic large cell lymphoma (ALCL). Med Pediatr Oncol 2001; 37: 97\u2013102.","journal-title":"Med Pediatr Oncol"},{"key":"BFbcj20128_CR100","doi-asserted-by":"crossref","first-page":"670","DOI":"10.1182\/blood-2007-02-066852","volume":"110","author":"C Damm-Welk","year":"2007","unstructured":"Damm-Welk C, Busch K, Burkhardt B, Schieferstein J, Viehmann S, Oschlies I et al. Prognostic significance of circulating tumor cells in bone marrow or peripheral blood as detected by qualitative and quantitative PCR in pediatric NPM-ALK-positive anaplastic large-cell lymphoma. Blood 2007; 110: 670\u2013677.","journal-title":"Blood"},{"key":"BFbcj20128_CR101","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1038\/leu.2008.184","volume":"23","author":"L Mussolin","year":"2009","unstructured":"Mussolin L, Bonvini P, Ait-Tahar K, Pillon M, Tridello G, Buffardi S et al. Kinetics of humoral response to ALK and its relationship with minimal residual disease in pediatric ALCL. Leukemia 2009; 23: 400\u2013402.","journal-title":"Leukemia"},{"key":"BFbcj20128_CR102","doi-asserted-by":"crossref","first-page":"3314","DOI":"10.1182\/blood-2009-11-251892","volume":"115","author":"K Ait-Tahar","year":"2010","unstructured":"Ait-Tahar K, Damm-Welk C, Burkhardt B, Zimmermann M, Klapper W, Reiter A et al. Correlation of the autoantibody response to the ALK oncoantigen in pediatric anaplastic lymphoma kinase-positive anaplastic large cell lymphoma with tumor dissemination and relapse risk. Blood 2010; 115: 3314\u20133319.","journal-title":"Blood"},{"key":"BFbcj20128_CR103","first-page":"42","volume":"3","author":"L Lamant","year":"2009","unstructured":"Lamant L, McCarthy K, d\u2019Amore ESG, Klapper W, Nakagawa A, Fraga M et al. Prognostic impact of morphologic and phenotypic features of childhood ALK-positive anaplastic large cell lymphoma (ALCL): results of the ALCL99 study. Hematol Meeting Rep 2009, (abstract); 3: 42.","journal-title":"Hematol Meeting Rep"},{"key":"BFbcj20128_CR104","doi-asserted-by":"crossref","first-page":"2467","DOI":"10.1182\/blood.V84.8.2467.2467","volume":"84","author":"JT Sandlund","year":"1994","unstructured":"Sandlund JT, Pui CH, Roberts WM, Santana VM, Morris SW, Berard CW et al. Clinicopathologic features and treatment outcome of children with large-cell lymphoma and the t(2;5)(p23;q35). Blood 1994; 84: 2467\u20132471.","journal-title":"Blood"},{"key":"BFbcj20128_CR105","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1002\/mpo.2950210603","volume":"21","author":"V Vecchi","year":"1993","unstructured":"Vecchi V, Burnelli R, Pileri S, Rosito P, Sabattini E, Civino A et al. Anaplastic large cell lymphoma (Ki-1+\/CD30+) in childhood. Med Pediatr Oncol 1993; 21: 402\u2013410.","journal-title":"Med Pediatr Oncol"},{"key":"BFbcj20128_CR106","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1200\/JCO.1994.12.5.899","volume":"12","author":"A Reiter","year":"1994","unstructured":"Reiter A, Schrappe M, Tiemann M, Parwaresch R, Zimmermann M, Yakisan E et al. Successful treatment strategy for Ki-1 anaplastic large-cell lymphoma of childhood: a prospective analysis of 62 patients enrolled in three consecutive Berlin-Frankfurt-Munster group studies. J Clin Oncol 1994; 12: 899\u2013908.","journal-title":"J Clin Oncol"},{"key":"BFbcj20128_CR107","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1002\/(SICI)1097-0142(20000101)88:1<186::AID-CNCR26>3.0.CO;2-5","volume":"88","author":"J Mora","year":"2000","unstructured":"Mora J, Filippa DA, Thaler HT, Polyak T, Cranor ML, Wollner N . Large cell non-Hodgkin lymphoma of childhood: analysis of 78 consecutive patients enrolled in 2 consecutive protocols at the Memorial Sloan-Kettering Cancer Center. Cancer 2000; 88: 186\u2013197.","journal-title":"Cancer"},{"key":"BFbcj20128_CR108","doi-asserted-by":"crossref","first-page":"3065","DOI":"10.1200\/JCO.2011.34.8417","volume":"29","author":"W Woessmann","year":"2011","unstructured":"Woessmann W, Zimmermann M, Lenhard M, Burkhardt B, Rossig C, Kremens B et al. Relapsed or refractory anaplastic large-cell lymphoma in children and adolescents after Berlin-Frankfurt-Muenster (BFM)-type first-line therapy: a BFM-group study. J Clin Oncol 2011; 29: 3065\u20133071.","journal-title":"J Clin Oncol"},{"key":"BFbcj20128_CR109","doi-asserted-by":"crossref","first-page":"594","DOI":"10.1111\/j.1365-2141.2005.05910.x","volume":"132","author":"T Mori","year":"2006","unstructured":"Mori T, Takimoto T, Katano N, Kikuchi A, Tabuchi K, Kobayashi R et al. Recurrent childhood anaplastic large cell lymphoma: a retrospective analysis of registered cases in Japan. Br J Haematol 2006; 132: 594\u2013597.","journal-title":"Br J Haematol"},{"key":"BFbcj20128_CR110","doi-asserted-by":"crossref","first-page":"3987","DOI":"10.1200\/JCO.2010.28.5999","volume":"28","author":"MC Le Deley","year":"2010","unstructured":"Le Deley MC, Rosolen A, Williams DM, Horibe K, Wrobel G, Attarbaschi A et al. Vinblastine in children and adolescents with high-risk anaplastic large-cell lymphoma: results of the randomized ALCL99-vinblastine trial. J Clin Oncol 2010; 28: 3987\u20133993.","journal-title":"J Clin Oncol"},{"key":"BFbcj20128_CR111","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1111\/j.1600-0609.2005.00422.x","volume":"75","author":"S Cesaro","year":"2005","unstructured":"Cesaro S, Pillon M, Visintin G, Putti MC, Gazzola MV, D\u2019Amore E et al. Unrelated bone marrow transplantation for high-risk anaplastic large cell lymphoma in pediatric patients: a single center case series. Eur J Haematol 2005; 75: 22\u201326.","journal-title":"Eur J Haematol"},{"key":"BFbcj20128_CR112","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1111\/j.1365-2141.2006.06004.x","volume":"133","author":"W Woessmann","year":"2006","unstructured":"Woessmann W, Peters C, Lenhard M, Burkhardt B, Sykora KW, Dilloo D et al. Allogeneic haematopoietic stem cell transplantation in relapsed or refractory anaplastic large cell lymphoma of children and adolescents--a Berlin-Frankfurt-Munster group report. Br J Haematol 2006; 133: 176\u2013182.","journal-title":"Br J Haematol"},{"key":"BFbcj20128_CR113","doi-asserted-by":"crossref","first-page":"1848","DOI":"10.1182\/blood-2007-07-099317","volume":"111","author":"NL Bartlett","year":"2008","unstructured":"Bartlett NL, Younes A, Carabasi MH, Forero A, Rosenblatt JD, Leonard JP et al. A phase 1 multidose study of SGN-30 immunotherapy in patients with refractory or recurrent CD30+ hematologic malignancies. Blood 2008; 111: 1848\u20131854.","journal-title":"Blood"},{"key":"BFbcj20128_CR114","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1111\/j.1365-2141.2009.07740.x","volume":"146","author":"A Forero-Torres","year":"2009","unstructured":"Forero-Torres A, Leonard JP, Younes A, Rosenblatt JD, Brice P, Bartlett NL et al. A phase II study of SGN-30 (anti-CD30mAb) in Hodgkin lymphoma or systemic anaplastic large cell lymphoma. Br J Haematol 2009; 146: 171\u2013179.","journal-title":"Br J Haematol"},{"key":"BFbcj20128_CR115","doi-asserted-by":"crossref","first-page":"1812","DOI":"10.1056\/NEJMoa1002965","volume":"363","author":"A Younes","year":"2010","unstructured":"Younes A, Bartlett NL, Leonard JP, Kennedy DA, Lynch CM, Sievers EL et al. Brentuximab vedotin (SGN-35) for relapsed CD30-positive lymphomas. N Engl J Med 2010; 363: 1812\u20131821.","journal-title":"N Engl J Med"},{"key":"BFbcj20128_CR116","doi-asserted-by":"crossref","first-page":"8500","DOI":"10.1200\/jco.2009.27.15_suppl.8500","volume":"17","author":"N Bartlett","year":"2009","unstructured":"Bartlett N, Forero-Torres A, Rosenblatt J, Fanale M, Horning SJ, Thompson S et al. Complete remissions with SGN-35 weekly dosing: a phase I dose-escalation study in relapsed\/refractory Hodgkin lymphoma or systemic ALCL patients. J Clin Oncol 2009, (abstract); 17: 8500.","journal-title":"J Clin Oncol"},{"key":"BFbcj20128_CR117","doi-asserted-by":"crossref","first-page":"1006","DOI":"10.1182\/blood.V112.11.1006.1006","volume":"112","author":"A Younes","year":"2008","unstructured":"Younes A, Forero-Torres A, Bartlett NL, Leonard JP, Lynch C, Kennedy DA et al. Multiple complete responses in a phase 1 dose-escalation study of the antibody-drug conjugate SGN-35 in patients with relapsed or refractory CD30-positive lymphomas. Blood 2008, (abstract); 112: 1006.","journal-title":"Blood"},{"key":"BFbcj20128_CR118","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1073\/pnas.0609412103","volume":"104","author":"AV Galkin","year":"2007","unstructured":"Galkin AV, Melnick JS, Kim S, Hood TL, Li N, Li L et al. Identification of NVP-TAE684, a potent, selective, and efficacious inhibitor of NPM-ALK. Proc Natl Acad Sci USA 2007; 104: 270\u2013275.","journal-title":"Proc Natl Acad Sci USA"},{"key":"BFbcj20128_CR119","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1056\/NEJMc1013224","volume":"364","author":"C Gambacorti-Passerini","year":"2011","unstructured":"Gambacorti-Passerini C, Messa C, Pogliani EM . Crizotinib in anaplastic large-cell lymphoma. N Engl J Med 2011; 364: 775\u2013776.","journal-title":"N Engl J Med"},{"key":"BFbcj20128_CR120","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1042\/BJ20090387","volume":"420","author":"RH Palmer","year":"2009","unstructured":"Palmer RH, Vernersson E, Grabbe C, Hallberg B . Anaplastic lymphoma kinase: signalling in development and disease. Biochem J 2009; 420: 345\u2013361.","journal-title":"Biochem J"},{"key":"BFbcj20128_CR121","doi-asserted-by":"crossref","first-page":"2566","DOI":"10.1002\/cncr.22718","volume":"109","author":"S Cannella","year":"2007","unstructured":"Cannella S, Santoro A, Bruno G, Pillon M, Mussolin L, Mangili G et al. Germline mutations of the perforin gene are a frequent occurrence in childhood anaplastic large cell lymphoma. Cancer 2007; 109: 2566\u20132571.","journal-title":"Cancer"},{"key":"BFbcj20128_CR122","doi-asserted-by":"crossref","first-page":"4424","DOI":"10.1182\/blood-2004-04-1477","volume":"105","author":"R Clementi","year":"2005","unstructured":"Clementi R, Locatelli F, Dupre L, Garaventa A, Emmi L, Bregni M et al. A proportion of patients with lymphoma may harbor mutations of the perforin gene. Blood 2005; 105: 4424\u20134428.","journal-title":"Blood"},{"key":"BFbcj20128_CR123","doi-asserted-by":"crossref","first-page":"2550","DOI":"10.1158\/0008-5472.CAN-08-1808","volume":"69","author":"RR Singh","year":"2009","unstructured":"Singh RR, Cho-Vega JH, Davuluri Y, Ma S, Kasbidi F, Milito C et al. Sonic hedgehog signaling pathway is activated in ALK-positive anaplastic large cell lymphoma. Cancer Res 2009; 69: 2550\u20132558.","journal-title":"Cancer Res"},{"key":"BFbcj20128_CR124","doi-asserted-by":"crossref","first-page":"1585","DOI":"10.1182\/blood-2009-02-204735","volume":"114","author":"MS Lim","year":"2009","unstructured":"Lim MS, Carlson ML, Crockett DK, Fillmore GC, Abbott DR, Elenitoba-Johnson OF et al. The proteomic signature of NPM\/ALK reveals deregulation of multiple cellular pathways. Blood 2009; 114: 1585\u20131595.","journal-title":"Blood"},{"key":"BFbcj20128_CR125","doi-asserted-by":"crossref","first-page":"1787","DOI":"10.1074\/mcp.R600005-MCP200","volume":"5","author":"MS Lim","year":"2006","unstructured":"Lim MS, Elenitoba-Johnson KS . Mass spectrometry-based proteomic studies of human anaplastic large cell lymphoma. Mol Cell Proteomics 2006; 5: 1787\u20131798.","journal-title":"Mol Cell Proteomics"},{"key":"BFbcj20128_CR126","first-page":"44","volume":"3","author":"M Lim","year":"2009","unstructured":"Lim M, Tygeson J, Seiler C, Crockett D, Satwani P, Perkins S et al. Proteomic analysis of denileukin diftitox (Ontak) as a potential therapeutic agent for ALCL. Hematol Meeting Rep 2009, (abstract); 3: 44.","journal-title":"Hematol Meeting Rep"},{"key":"BFbcj20128_CR127","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1111\/j.1365-2141.2007.06689.x","volume":"138","author":"RR Miles","year":"2007","unstructured":"Miles RR, Cairo MS, Satwani P, Zwick DL, Lones MA, Sposto R et al. Immunophenotypic identification of possible therapeutic targets in paediatric non-Hodgkin lymphomas: a children's oncology group report. Br J Haematol 2007; 138: 506\u2013512.","journal-title":"Br J Haematol"},{"key":"BFbcj20128_CR128","first-page":"1559","volume":"62","author":"P Bonvini","year":"2002","unstructured":"Bonvini P, Gastaldi T, Falini B, Rosolen A . Nucleophosmin-anaplastic lymphoma kinase (NPM-ALK), a novel Hsp90-client tyrosine kinase: down-regulation of NPM-ALK expression and tyrosine phosphorylation in ALK(+) CD30(+) lymphoma cells by the Hsp90 antagonist 17-allylamino,17-demethoxygeldanamycin. Cancer Res 2002; 62: 1559\u20131566.","journal-title":"Cancer Res"},{"key":"BFbcj20128_CR129","first-page":"2194","volume":"61","author":"A Slupianek","year":"2001","unstructured":"Slupianek A, Nieborowska-Skorska M, Hoser G, Morrione A, Majewski M, Xue L et al. Role of phosphatidylinositol 3-kinase-Akt pathway in nucleophosmin\/anaplastic lymphoma kinase-mediated lymphomagenesis. Cancer Res 2001; 61: 2194\u20132199.","journal-title":"Cancer Res"},{"key":"BFbcj20128_CR130","doi-asserted-by":"crossref","first-page":"784","DOI":"10.1002\/pbc.21293","volume":"50","author":"R Windsor","year":"2008","unstructured":"Windsor R, Stiller C, Webb D . Peripheral T-cell lymphoma in childhood: population-based experience in the United Kingdom over 20 years. Pediatr Blood Cancer 2008; 50: 784\u2013787.","journal-title":"Pediatr Blood Cancer"},{"key":"BFbcj20128_CR131","doi-asserted-by":"crossref","unstructured":"A clinical evaluation of the International Lymphoma Study Group classification of non-Hodgkin's lymphoma. The Non-Hodgkin's Lymphoma Classification Project. Blood 1997; 89: 3909\u20133918.","DOI":"10.1182\/blood.V89.11.3909"},{"key":"BFbcj20128_CR132","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1002\/hon.786","volume":"24","author":"T Rudiger","year":"2006","unstructured":"Rudiger T, Geissinger E, Muller-Hermelink HK . \u2018Normal counterparts\u2019 of nodal peripheral T-cell lymphoma. Hematol Oncol 2006; 24: 175\u2013180.","journal-title":"Hematol Oncol"},{"key":"BFbcj20128_CR133","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1111\/j.1365-2141.2008.07042.x","volume":"141","author":"M Nelson","year":"2008","unstructured":"Nelson M, Horsman DE, Weisenburger DD, Gascoyne RD, Dave BJ, Loberiza FR et al. Cytogenetic abnormalities and clinical correlations in peripheral T-cell lymphoma. Br J Haematol 2008; 141: 461\u2013469.","journal-title":"Br J Haematol"},{"key":"BFbcj20128_CR134","doi-asserted-by":"crossref","first-page":"1837","DOI":"10.1016\/S0002-9440(10)63742-X","volume":"164","author":"A Zettl","year":"2004","unstructured":"Zettl A, Rudiger T, Konrad MA, Chott A, Simonitsch-Klupp I, Sonnen R et al. Genomic profiling of peripheral T-cell lymphoma, unspecified, and anaplastic large T-cell lymphoma delineates novel recurrent chromosomal alterations. Am J Pathol 2004; 164: 1837\u20131848.","journal-title":"Am J Pathol"},{"key":"BFbcj20128_CR135","doi-asserted-by":"crossref","first-page":"2254","DOI":"10.1038\/sj.leu.2403960","volume":"19","author":"B Martinez-Delgado","year":"2005","unstructured":"Martinez-Delgado B, Cuadros M, Honrado E, Ruiz de la Parte A, Roncador G, Alves J et al. Differential expression of NF-kappaB pathway genes among peripheral T-cell lymphomas. Leukemia 2005; 19: 2254\u20132263.","journal-title":"Leukemia"},{"key":"BFbcj20128_CR136","doi-asserted-by":"crossref","first-page":"1560","DOI":"10.1038\/sj.onc.1209178","volume":"25","author":"B Ballester","year":"2006","unstructured":"Ballester B, Ramuz O, Gisselbrecht C, Doucet G, Loi L, Loriod B et al. Gene expression profiling identifies molecular subgroups among nodal peripheral T-cell lymphomas. Oncogene 2006; 25: 1560\u20131570.","journal-title":"Oncogene"},{"key":"BFbcj20128_CR137","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1002\/pbc.21543","volume":"51","author":"RE Hutchison","year":"2008","unstructured":"Hutchison RE, Laver JH, Chang M, Muzzafar T, Desai S, Murphy S et al. Non-anaplastic peripheral t-cell lymphoma in childhood and adolescence: a Children's Oncology Group study. Pediatr Blood Cancer 2008; 51: 29\u201333.","journal-title":"Pediatr Blood Cancer"},{"key":"BFbcj20128_CR138","first-page":"76","volume":"92","author":"C Gisselbrecht","year":"1998","unstructured":"Gisselbrecht C, Gaulard P, Lepage E, Coiffier B, Briere J, Haioun C et al. Prognostic significance of T-cell phenotype in aggressive non-Hodgkin's lymphomas. Groupe d\u2019Etudes des Lymphomes de l\u2019Adulte (GELA). Blood 1998; 92: 76\u201382.","journal-title":"Blood"},{"key":"BFbcj20128_CR139","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1016\/j.blre.2007.03.001","volume":"21","author":"KJ Savage","year":"2007","unstructured":"Savage KJ . Peripheral T-cell lymphomas. Blood Rev 2007; 21: 201\u2013216.","journal-title":"Blood Rev"},{"key":"BFbcj20128_CR140","doi-asserted-by":"crossref","first-page":"1467","DOI":"10.1093\/annonc\/mdh392","volume":"15","author":"KJ Savage","year":"2004","unstructured":"Savage KJ, Chhanabhai M, Gascoyne RD, Connors JM . Characterization of peripheral T-cell lymphomas in a single North American institution by the WHO classification. Ann Oncol 2004; 15: 1467\u20131475.","journal-title":"Ann Oncol"},{"key":"BFbcj20128_CR141","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1111\/j.1365-2141.2006.06164.x","volume":"134","author":"T Kewalramani","year":"2006","unstructured":"Kewalramani T, Zelenetz AD, Teruya-Feldstein J, Hamlin P, Yahalom J, Horwitz S et al. Autologous transplantation for relapsed or primary refractory peripheral T-cell lymphoma. Br J Haematol 2006; 134: 202\u2013207.","journal-title":"Br J Haematol"},{"key":"BFbcj20128_CR142","doi-asserted-by":"crossref","first-page":"1496","DOI":"10.1080\/10428190701435275","volume":"48","author":"C Paolo","year":"2007","unstructured":"Paolo C, Lucia F, Anna D . Hematopoietic stem cell transplantation in peripheral T-cell lymphomas. Leuk Lymphoma 2007; 48: 1496\u20131501.","journal-title":"Leuk Lymphoma"},{"key":"BFbcj20128_CR143","doi-asserted-by":"crossref","first-page":"1533","DOI":"10.1038\/sj.leu.2404306","volume":"20","author":"P Corradini","year":"2006","unstructured":"Corradini P, Tarella C, Zallio F, Dodero A, Zanni M, Valagussa P et al. Long-term follow-up of patients with peripheral T-cell lymphomas treated up-front with high-dose chemotherapy followed by autologous stem cell transplantation. Leukemia 2006; 20: 1533\u20131538.","journal-title":"Leukemia"},{"key":"BFbcj20128_CR144","doi-asserted-by":"crossref","first-page":"953","DOI":"10.1038\/sj.bmt.1704040","volume":"31","author":"P Mollee","year":"2003","unstructured":"Mollee P, Lazarus HM, Lipton J . Why aren\u2019t we performing more allografts for aggressive non-Hodgkin's lymphoma? Bone Marrow Transplant 2003; 31: 953\u2013960.","journal-title":"Bone Marrow Transplant"},{"key":"BFbcj20128_CR145","doi-asserted-by":"crossref","first-page":"2172","DOI":"10.1200\/JCO.2004.12.050","volume":"22","author":"P Corradini","year":"2004","unstructured":"Corradini P, Dodero A, Zallio F, Caracciolo D, Casini M, Bregni M et al. Graft-versus-lymphoma effect in relapsed peripheral T-cell non-Hodgkin's lymphomas after reduced-intensity conditioning followed by allogeneic transplantation of hematopoietic cells. J Clin Oncol 2004; 22: 2172\u20132176.","journal-title":"J Clin Oncol"},{"key":"BFbcj20128_CR146","doi-asserted-by":"crossref","first-page":"2474","DOI":"10.1182\/blood-2003-09-3080","volume":"103","author":"A Gallamini","year":"2004","unstructured":"Gallamini A, Stelitano C, Calvi R, Bellei M, Mattei D, Vitolo U et al. Peripheral T-cell lymphoma unspecified (PTCL-U): a new prognostic model from a retrospective multicentric clinical study. Blood 2004; 103: 2474\u20132479.","journal-title":"Blood"},{"key":"BFbcj20128_CR147","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1046\/j.1365-2141.2001.02743.x","volume":"113","author":"S Sallah","year":"2001","unstructured":"Sallah S, Wan JY, Nguyen NP . Treatment of refractory T-cell malignancies using gemcitabine. Br J Haematol 2001; 113: 185\u2013187.","journal-title":"Br J Haematol"},{"key":"BFbcj20128_CR148","doi-asserted-by":"crossref","first-page":"2486","DOI":"10.1182\/blood.V104.11.2486.2486","volume":"104","author":"MS Czuczman","year":"2004","unstructured":"Czuczman MS, Porcu P, Johnson J, Niedzwiecki D, Canellos GP, Cheson BD . CALGB 59901: results of a phase II study of 506U78 in CTCL and PTCL. Blood 2004, (abstract); 104: 2486.","journal-title":"Blood"},{"key":"BFbcj20128_CR149","doi-asserted-by":"crossref","unstructured":"Piekarz R, Wright J, Frye R, Allen SL, Craig M, Geskin L et al. Results of a phase 2 NCI multicenter study of romidepsin in patients with relapsed peripheral T-cell lymphoma (PTCL). 2008, (abstract); 112: 1567.","DOI":"10.1182\/blood.V112.11.1567.1567"},{"key":"BFbcj20128_CR150","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1093\/annonc\/mdm579","volume":"19","author":"D Aguiar Bujanda","year":"2008","unstructured":"Aguiar Bujanda D . Complete response of relapsed angioimmunoblastic T-cell lymphoma following therapy with bevacizumab. Ann Oncol 2008; 19: 396\u2013397.","journal-title":"Ann Oncol"},{"key":"BFbcj20128_CR151","doi-asserted-by":"crossref","first-page":"1993","DOI":"10.1038\/sj.leu.2403936","volume":"19","author":"I Bruns","year":"2005","unstructured":"Bruns I, Fox F, Reinecke P, Kobbe G, Kronenwett R, Jung G et al. Complete remission in a patient with relapsed angioimmunoblastic T-cell lymphoma following treatment with bevacizumab. Leukemia 2005; 19: 1993\u20131995.","journal-title":"Leukemia"},{"key":"BFbcj20128_CR152","doi-asserted-by":"crossref","first-page":"4357","DOI":"10.1200\/JCO.2008.20.8470","volume":"27","author":"OA O\u2019Connor","year":"2009","unstructured":"O\u2019Connor OA, Horwitz S, Hamlin P, Portlock C, Moskowitz CH, Sarasohn D et al. Phase II-I-II study of two different doses and schedules of pralatrexate, a high-affinity substrate for the reduced folate carrier, in patients with relapsed or refractory lymphoma reveals marked activity in T-cell malignancies. J Clin Oncol 2009; 27: 4357\u20134364.","journal-title":"J Clin Oncol"},{"key":"BFbcj20128_CR153","doi-asserted-by":"crossref","unstructured":"O\u2019Connor OA, Pro B, Pinter-Brown L, Popplewell L, Barlett N, Shustov A et al. PROPEL: a multi-center phase 2 open-label study of pralatrexate (PDX) with vitamin B12 and folic acid supplementation in patients with replapsed or refractory peripheral T-cell lymphoma. 2008, (abstract); 112: 261.","DOI":"10.1182\/blood.V112.11.261.261"},{"key":"BFbcj20128_CR154","doi-asserted-by":"crossref","first-page":"3058","DOI":"10.1182\/blood-2004-07-2911","volume":"105","author":"RZ Orlowski","year":"2005","unstructured":"Orlowski RZ, Voorhees PM, Garcia RA, Hall MD, Kudrik FJ, Allred T et al. Phase 1 trial of the proteasome inhibitor bortezomib and pegylated liposomal doxorubicin in patients with advanced hematologic malignancies. Blood 2005; 105: 3058\u20133065.","journal-title":"Blood"},{"key":"BFbcj20128_CR155","doi-asserted-by":"crossref","first-page":"4293","DOI":"10.1200\/JCO.2007.11.4207","volume":"25","author":"PL Zinzani","year":"2007","unstructured":"Zinzani PL, Musuraca G, Tani M, Stefoni V, Marchi E, Fina M et al. Phase II trial of proteasome inhibitor bortezomib in patients with relapsed or refractory cutaneous T-cell lymphoma. J Clin Oncol 2007; 25: 4293\u20134297.","journal-title":"J Clin Oncol"},{"key":"BFbcj20128_CR156","doi-asserted-by":"crossref","first-page":"2079","DOI":"10.1093\/annonc\/mdn431","volume":"19","author":"J Lee","year":"2008","unstructured":"Lee J, Suh C, Kang HJ, Ryoo BY, Huh J, Ko YH et al. Phase I study of proteasome inhibitor bortezomib plus CHOP in patients with advanced, aggressive T-cell or NK\/T-cell lymphoma. Ann Oncol 2008; 19: 2079\u20132083.","journal-title":"Ann Oncol"},{"key":"BFbcj20128_CR157","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1111\/j.1600-0609.2009.01239.x","volume":"82","author":"U Heider","year":"2009","unstructured":"Heider U, Rademacher J, Lamottke B, Mieth M, Moebs M, von Metzler I et al. Synergistic interaction of the histone deacetylase inhibitor SAHA with the proteasome inhibitor bortezomib in cutaneous T cell lymphoma. Eur J Haematol 2009; 82: 440\u2013449.","journal-title":"Eur J Haematol"},{"key":"BFbcj20128_CR158","doi-asserted-by":"crossref","first-page":"2920","DOI":"10.1182\/blood-2003-10-3389","volume":"103","author":"G Enblad","year":"2004","unstructured":"Enblad G, Hagberg H, Erlanson M, Lundin J, MacDonald AP, Repp R et al. A pilot study of alemtuzumab (anti-CD52 monoclonal antibody) therapy for patients with relapsed or chemotherapy-refractory peripheral T-cell lymphomas. Blood 2004; 103: 2920\u20132924.","journal-title":"Blood"},{"key":"BFbcj20128_CR159","doi-asserted-by":"crossref","first-page":"2316","DOI":"10.1182\/blood-2007-02-074641","volume":"110","author":"A Gallamini","year":"2007","unstructured":"Gallamini A, Zaja F, Patti C, Billio A, Specchia MR, Tucci A et al. Alemtuzumab (Campath-1H) and CHOP chemotherapy as first-line treatment of peripheral T-cell lymphoma: results of a GITIL (Gruppo Italiano Terapie Innovative nei Linfomi) prospective multicenter trial. Blood 2007; 110: 2316\u20132323.","journal-title":"Blood"},{"key":"BFbcj20128_CR160","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1097\/MOH.0b013e32832ad69a","volume":"16","author":"BD Cheson","year":"2009","unstructured":"Cheson BD . Novel therapies for peripheral T-cell non-Hodgkin's lymphomas. Curr Opin Hematol 2009; 16: 299\u2013305.","journal-title":"Curr Opin Hematol"},{"issue":"1","key":"BFbcj20128_CR161","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1182\/asheducation-2008.1.289","volume":"2008","author":"S. M. Horwitz","year":"2008","unstructured":"Horwitz SM . Novel therapies and role of transplant in the treatment of peripheral T-cell lymphomas. Hematol Am Soc Hematol Educ Program 2008, 289\u2013296.","journal-title":"Hematology"},{"key":"BFbcj20128_CR162","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1007\/s12308-009-0035-y","volume":"2","author":"MS Lim","year":"2009","unstructured":"Lim MS . Commentary on the WHO 2008 classification of neoplasms arising from histiocytic and other accessory cells. J Hematopathol 2009; 2: 75\u201376.","journal-title":"J Hematopathol"},{"key":"BFbcj20128_CR163","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1097\/MPG.0b013e31802f6424","volume":"44","author":"AC Mackey","year":"2007","unstructured":"Mackey AC, Green L, Liang LC, Dinndorf P, Avigan M . Hepatosplenic T cell lymphoma associated with infliximab use in young patients treated for inflammatory bowel disease. J Pediatr Gastroenterol Nutr 2007; 44: 265\u2013267.","journal-title":"J Pediatr Gastroenterol Nutr"},{"key":"BFbcj20128_CR164","doi-asserted-by":"crossref","first-page":"1071","DOI":"10.1182\/blood-2008-07-166363","volume":"113","author":"K Miyazaki","year":"2009","unstructured":"Miyazaki K, Yamaguchi M, Imai H, Kobayashi T, Tamaru S, Nishii K et al. Gene expression profiling of peripheral T-cell lymphoma including gammadelta T-cell lymphoma. Blood 2009; 113: 1071\u20131074.","journal-title":"Blood"},{"key":"BFbcj20128_CR165","doi-asserted-by":"crossref","first-page":"4261","DOI":"10.1182\/blood-2003-05-1675","volume":"102","author":"K Belhadj","year":"2003","unstructured":"Belhadj K, Reyes F, Farcet JP, Tilly H, Bastard C, Angonin R et al. Hepatosplenic gammadelta T-cell lymphoma is a rare clinicopathologic entity with poor outcome: report on a series of 21 patients. Blood 2003; 102: 4261\u20134269.","journal-title":"Blood"},{"key":"BFbcj20128_CR166","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1097\/01.mph.0000187431.37369.f5","volume":"27","author":"JA Domm","year":"2005","unstructured":"Domm JA, Thompson M, Kuttesch JF, Acra S, Frangoul H . Allogeneic bone marrow transplantation for chemotherapy-refractory hepatosplenic gammadelta T-cell lymphoma: case report and review of the literature. J Pediatr Hematol Oncol 2005; 27: 607\u2013610.","journal-title":"J Pediatr Hematol Oncol"},{"key":"BFbcj20128_CR167","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1080\/10428190601126941","volume":"48","author":"T Konuma","year":"2007","unstructured":"Konuma T, Ooi J, Takahashi S, Tomonari A, Tsukada N, Kobayashi T et al. Allogeneic stem cell transplantation for hepatosplenic gammadelta T-cell lymphoma. Leukemia Lymphoma 2007; 48: 630\u2013632.","journal-title":"Leukemia Lymphoma"},{"key":"BFbcj20128_CR168","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1097\/MPH.0b013e31817588e8","volume":"30","author":"K Medhi","year":"2008","unstructured":"Medhi K, Kumar R, Rishi A, Kumar L, Bakhshi S . Subcutaneous panniculitislike T-cell lymphoma with hemophagocytosis: complete remission with BFM-90 protocol. J Pediatr Hematol Oncol 2008; 30: 558\u2013561.","journal-title":"J Pediatr Hematol Oncol"},{"key":"BFbcj20128_CR169","doi-asserted-by":"crossref","first-page":"838","DOI":"10.1182\/blood-2007-04-087288","volume":"111","author":"R Willemze","year":"2008","unstructured":"Willemze R, Jansen PM, Cerroni L, Berti E, Santucci M, Assaf C et al. Subcutaneous panniculitis-like T-cell lymphoma: definition, classification, and prognostic factors: an EORTC Cutaneous Lymphoma Group Study of 83 cases. Blood 2008; 111: 838\u2013845.","journal-title":"Blood"},{"key":"BFbcj20128_CR170","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1111\/j.1440-1827.2008.02213.x","volume":"58","author":"K Ohshima","year":"2008","unstructured":"Ohshima K, Kimura H, Yoshino T, Kim CW, Ko YH, Lee SS et al. Proposed categorization of pathological states of EBV-associated T\/natural killer-cell lymphoproliferative disorder (LPD) in children and young adults: overlap with chronic active EBV infection and infantile fulminant EBV T-LPD. Pathol Int 2008; 58: 209\u2013217.","journal-title":"Pathol Int"},{"key":"BFbcj20128_CR171","doi-asserted-by":"crossref","first-page":"1472","DOI":"10.1093\/annonc\/mdp064","volume":"20","author":"JI Cohen","year":"2009","unstructured":"Cohen JI, Kimura H, Nakamura S, Ko YH, Jaffe ES . Epstein-Barr virus-associated lymphoproliferative disease in non-immunocompromised hosts: a status report and summary of an international meeting, 8\u20139 September 2008. Ann Oncol 2009; 20: 1472\u20131482.","journal-title":"Ann Oncol"},{"key":"BFbcj20128_CR172","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1002\/ajh.21247","volume":"83","author":"E Sato","year":"2008","unstructured":"Sato E, Ohga S, Kuroda H, Yoshiba F, Nishimura M, Nagasawa M et al. Allogeneic hematopoietic stem cell transplantation for Epstein-Barr virus-associated T\/natural killer-cell lymphoproliferative disease in Japan. Am J Hematol 2008; 83: 721\u2013727.","journal-title":"Am J Hematol"},{"key":"BFbcj20128_CR173","doi-asserted-by":"crossref","first-page":"6058","DOI":"10.1038\/sj.onc.1208968","volume":"24","author":"FA Proietti","year":"2005","unstructured":"Proietti FA, Carneiro-Proietti AB, Catalan-Soares BC, Murphy EL . Global epidemiology of HTLV-I infection and associated diseases. Oncogene 2005; 24: 6058\u20136068.","journal-title":"Oncogene"},{"key":"BFbcj20128_CR174","doi-asserted-by":"crossref","first-page":"5131","DOI":"10.1038\/sj.onc.1206551","volume":"22","author":"M Matsuoka","year":"2003","unstructured":"Matsuoka M . Human T-cell leukemia virus type I and adult T-cell leukemia. Oncogene 2003; 22: 5131\u20135140.","journal-title":"Oncogene"},{"key":"BFbcj20128_CR175","doi-asserted-by":"crossref","first-page":"1583","DOI":"10.1089\/08892220050192994","volume":"16","author":"XH Li","year":"2000","unstructured":"Li XH, Gaynor RB . Mechanisms of NF-kappaB activation by the HTLV type 1 tax protein. AIDS Res Hum Retroviruses 2000; 16: 1583\u20131590.","journal-title":"AIDS Res Hum Retroviruses"},{"key":"BFbcj20128_CR176","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1146\/annurev.immunol.19.1.475","volume":"19","author":"M Yoshida","year":"2001","unstructured":"Yoshida M . Multiple viral strategies of HTLV-1 for dysregulation of cell growth control. Ann Rev Immunol 2001; 19: 475\u2013496.","journal-title":"Ann Rev Immunol"},{"key":"BFbcj20128_CR177","doi-asserted-by":"crossref","first-page":"2755","DOI":"10.1182\/blood-2008-06-161729","volume":"113","author":"T Zhao","year":"2009","unstructured":"Zhao T, Yasunaga J, Satou Y, Nakao M, Takahashi M, Fujii M et al. Human T-cell leukemia virus type 1 bZIP factor selectively suppresses the classical pathway of NF-kappaB. Blood 2009; 113: 2755\u20132764.","journal-title":"Blood"},{"key":"BFbcj20128_CR178","doi-asserted-by":"crossref","first-page":"3788","DOI":"10.1182\/blood-2008-04-154286","volume":"112","author":"J Arnold","year":"2008","unstructured":"Arnold J, Zimmerman B, Li M, Lairmore MD, Green PL . Human T-cell leukemia virus type-1 antisense-encoded gene, Hbz, promotes T-lymphocyte proliferation. Blood 2008; 112: 3788\u20133797.","journal-title":"Blood"},{"key":"BFbcj20128_CR179","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1038\/sj.leu.2403176","volume":"18","author":"B Arnulf","year":"2004","unstructured":"Arnulf B, Thorel M, Poirot Y, Tamouza R, Boulanger E, Jaccard A et al. Loss of the ex vivo but not the reinducible CD8+ T-cell response to Tax in human T-cell leukemia virus type 1-infected patients with adult T-cell leukemia\/lymphoma. Leukemia 2004; 18: 126\u2013132.","journal-title":"Leukemia"},{"key":"BFbcj20128_CR180","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1532\/IJH97.07092","volume":"86","author":"M Kannagi","year":"2007","unstructured":"Kannagi M . Immunologic control of human T-cell leukemia virus type I and adult T-cell leukemia. Int J Hematol 2007; 86: 113\u2013117.","journal-title":"Int J Hematol"},{"key":"BFbcj20128_CR181","doi-asserted-by":"crossref","first-page":"5718","DOI":"10.4049\/jimmunol.177.8.5718","volume":"177","author":"T Kozako","year":"2006","unstructured":"Kozako T, Arima N, Toji S, Masamoto I, Akimoto M, Hamada H et al. Reduced frequency, diversity, and function of human T cell leukemia virus type 1-specific CD8+ T cell in adult T cell leukemia patients. J Immunol 2006; 177: 5718\u20135726.","journal-title":"J Immunol"},{"key":"BFbcj20128_CR182","doi-asserted-by":"crossref","first-page":"1373","DOI":"10.1136\/jcp.2007.052456","volume":"60","author":"E Matutes","year":"2007","unstructured":"Matutes E . Adult T-cell leukaemia\/lymphoma. J Clin Pathol 2007; 60: 1373\u20131377.","journal-title":"J Clin Pathol"},{"key":"BFbcj20128_CR183","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1111\/j.1600-0609.2007.01016.x","volume":"80","author":"K Ishitsuka","year":"2008","unstructured":"Ishitsuka K, Tamura K . Treatment of adult T-cell leukemia\/lymphoma: past, present, and future. Eur J Haematol 2008; 80: 185\u2013196.","journal-title":"Eur J Haematol"},{"key":"BFbcj20128_CR184","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1532\/IJH97.07070","volume":"86","author":"J Okamura","year":"2007","unstructured":"Okamura J, Uike N, Utsunomiya A, Tanosaki R . Allogeneic stem cell transplantation for adult T-cell leukemia\/lymphoma. Int J Hematol 2007; 86: 118\u2013125.","journal-title":"Int J Hematol"},{"key":"BFbcj20128_CR185","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1016\/j.bbmt.2008.04.014","volume":"14","author":"S Shiratori","year":"2008","unstructured":"Shiratori S, Yasumoto A, Tanaka J, Shigematsu A, Yamamoto S, Nishio M et al. A retrospective analysis of allogeneic hematopoietic stem cell transplantation for adult T cell leukemia\/lymphoma (ATL): clinical impact of graft-versus-leukemia\/lymphoma effect. Biol Blood Marrow Transplant 2008; 14: 817\u2013823.","journal-title":"Biol Blood Marrow Transplant"},{"key":"BFbcj20128_CR186","doi-asserted-by":"crossref","first-page":"3931","DOI":"10.1182\/blood-2008-10-185256","volume":"113","author":"WY Au","year":"2009","unstructured":"Au WY, Weisenburger DD, Intragumtornchai T, Nakamura S, Kim WS, Sng I et al. Clinical differences between nasal and extranasal natural killer\/T-cell lymphoma: a study of 136 cases from the International Peripheral T-Cell Lymphoma Project. Blood 2009; 113: 3931\u20133937.","journal-title":"Blood"},{"key":"BFbcj20128_CR187","doi-asserted-by":"crossref","first-page":"1139","DOI":"10.1038\/leu.2009.3","volume":"23","author":"J Iqbal","year":"2009","unstructured":"Iqbal J, Kucuk C, Deleeuw RJ, Srivastava G, Tam W, Geng H et al. Genomic analyses reveal global functional alterations that promote tumor growth and novel tumor suppressor genes in natural killer-cell malignancies. Leukemia 2009; 23: 1139\u20131151.","journal-title":"Leukemia"},{"key":"BFbcj20128_CR188","unstructured":"Cairo M, Day N, Shereck E, Ayello J, Elenitoba-Johnson K, Lim M (eds). Genomic and proteomic characterization of natural killer cell lymphoma: identification of therapeutic targets. T-cell Lymphoma Forum; 28\u201330 January 2010; Maui, HI."},{"key":"BFbcj20128_CR189","doi-asserted-by":"crossref","first-page":"4124","DOI":"10.1200\/JCO.2008.16.4558","volume":"26","author":"J Vose","year":"2008","unstructured":"Vose J, Armitage J, Weisenburger D . International peripheral T-cell and natural killer\/T-cell lymphoma study: pathology findings and clinical outcomes. J Clin Oncol 2008; 26: 4124\u20134130.","journal-title":"J Clin Oncol"},{"key":"BFbcj20128_CR190","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1111\/j.1365-2141.2007.06620.x","volume":"138","author":"Y Zhou","year":"2007","unstructured":"Zhou Y, Attygalle AD, Chuang SS, Diss T, Ye H, Liu H et al. Angioimmunoblastic T-cell lymphoma: histological progression associates with EBV and HHV6B viral load. Br J Haematol 2007; 138: 44\u201353.","journal-title":"Br J Haematol"},{"key":"BFbcj20128_CR191","doi-asserted-by":"crossref","first-page":"10703","DOI":"10.1158\/0008-5472.CAN-07-1708","volume":"67","author":"PP Piccaluga","year":"2007","unstructured":"Piccaluga PP, Agostinelli C, Califano A, Carbone A, Fantoni L, Ferrari S et al. Gene expression analysis of angioimmunoblastic lymphoma indicates derivation from T follicular helper cells and vascular endothelial growth factor deregulation. Cancer Res 2007; 67: 10703\u201310710.","journal-title":"Cancer Res"},{"key":"BFbcj20128_CR192","doi-asserted-by":"crossref","first-page":"1026","DOI":"10.1182\/blood-2009-06-227579","volume":"115","author":"J Iqbal","year":"2010","unstructured":"Iqbal J, Weisenburger DD, Greiner TC, Vose JM, McKeithan T, Kucuk C et al. Molecular signatures to improve diagnosis in peripheral T-cell lymphoma and prognostication in angioimmunoblastic T-cell lymphoma. Blood 2010; 115: 1026\u20131036.","journal-title":"Blood"},{"key":"BFbcj20128_CR193","doi-asserted-by":"crossref","first-page":"1473","DOI":"10.1097\/00000478-200311000-00012","volume":"27","author":"P Adam","year":"2003","unstructured":"Adam P, Katzenberger T, Seeberger H, Gattenlohner S, Wolf J, Steinlein C et al. A case of a diffuse large B-cell lymphoma of plasmablastic type associated with the t(2;5)(p23;q35) chromosome translocation. Am J Surg Pathol 2003; 27: 1473\u20131476.","journal-title":"Am J Surg Pathol"},{"key":"BFbcj20128_CR194","doi-asserted-by":"crossref","first-page":"1281","DOI":"10.1126\/science.8122112","volume":"263","author":"SW Morris","year":"1994","unstructured":"Morris SW, Kirstein MN, Valentine MB, Dittmer KG, Shapiro DN, Saltman DL et al. Fusion of a kinase gene, ALK, to a nucleolar protein gene, NPM, in non-Hodgkin's lymphoma. Science 1994; 263: 1281\u20131284.","journal-title":"Science"},{"key":"BFbcj20128_CR195","doi-asserted-by":"crossref","first-page":"2642","DOI":"10.1182\/blood-2003-04-1095","volume":"102","author":"M Onciu","year":"2003","unstructured":"Onciu M, Behm FG, Downing JR, Shurtleff SA, Raimondi SC, Ma Z et al. ALK-positive plasmablastic B-cell lymphoma with expression of the NPM-ALK fusion transcript: report of 2 cases. Blood 2003; 102: 2642\u20132644.","journal-title":"Blood"},{"key":"BFbcj20128_CR196","doi-asserted-by":"crossref","first-page":"1954","DOI":"10.1182\/blood.V86.5.1954.bloodjournal8651954","volume":"86","author":"M Shiota","year":"1995","unstructured":"Shiota M, Nakamura S, Ichinohasama R, Abe M, Akagi T, Takeshita M et al. Anaplastic large cell lymphomas expressing the novel chimeric protein p80NPM\/ALK: a distinct clinicopathologic entity. Blood 1995; 86: 1954\u20131960.","journal-title":"Blood"},{"key":"BFbcj20128_CR197","doi-asserted-by":"crossref","first-page":"3088","DOI":"10.1182\/blood.V93.9.3088.409k30_3088_3095","volume":"93","author":"L Lamant","year":"1999","unstructured":"Lamant L, Dastugue N, Pulford K, Delsol G, Mariame B . A new fusion gene TPM3-ALK in anaplastic large cell lymphoma created by a (1;2)(q25;p23) translocation. Blood 1999; 93: 3088\u20133095.","journal-title":"Blood"},{"key":"BFbcj20128_CR198","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1016\/S0002-9440(10)64550-6","volume":"157","author":"B Lawrence","year":"2000","unstructured":"Lawrence B, Perez-Atayde A, Hibbard MK, Rubin BP, Dal Cin P, Pinkus JL et al. TPM3-ALK and TPM4-ALK oncogenes in inflammatory myofibroblastic tumors. Am J Pathol 2000; 157: 377\u2013384.","journal-title":"Am J Pathol"},{"key":"BFbcj20128_CR199","first-page":"3614","volume":"94","author":"R Siebert","year":"1999","unstructured":"Siebert R, Gesk S, Harder L, Steinemann D, Grote W, Schlegelberger B et al. Complex variant translocation t(1;2) with TPM3-ALK fusion due to cryptic ALK gene rearrangement in anaplastic large-cell lymphoma. Blood 1999; 94: 3614\u20133617.","journal-title":"Blood"},{"key":"BFbcj20128_CR200","doi-asserted-by":"crossref","first-page":"1487","DOI":"10.1016\/S0002-9440(10)62574-6","volume":"160","author":"L Hernandez","year":"2002","unstructured":"Hernandez L, Bea S, Bellosillo B, Pinyol M, Falini B, Carbone A et al. Diversity of genomic breakpoints in TFG-ALK translocations in anaplastic large cell lymphomas: identification of a new TFG-ALK(XL) chimeric gene with transforming activity. Am J Pathol 2002; 160: 1487\u20131494.","journal-title":"Am J Pathol"},{"key":"BFbcj20128_CR201","doi-asserted-by":"crossref","first-page":"3265","DOI":"10.1182\/blood.V94.9.3265","volume":"94","author":"L Hernandez","year":"1999","unstructured":"Hernandez L, Pinyol M, Hernandez S, Bea S, Pulford K, Rosenwald A et al. TRK-fused gene (TFG) is a new partner of ALK in anaplastic large cell lymphoma producing two structurally different TFG-ALK translocations. Blood 1999; 94: 3265\u20133268.","journal-title":"Blood"},{"key":"BFbcj20128_CR202","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1016\/S0002-9440(10)64945-0","volume":"156","author":"GW Colleoni","year":"2000","unstructured":"Colleoni GW, Bridge JA, Garicochea B, Liu J, Filippa DA, Ladanyi M . ATIC-ALK: a novel variant ALK gene fusion in anaplastic large cell lymphoma resulting from the recurrent cryptic chromosomal inversion, inv(2)(p23q35). Am J Pathol 2000; 156: 781\u2013789.","journal-title":"Am J Pathol"},{"key":"BFbcj20128_CR203","doi-asserted-by":"crossref","first-page":"2144","DOI":"10.1182\/blood.V95.6.2144","volume":"95","author":"Z Ma","year":"2000","unstructured":"Ma Z, Cools J, Marynen P, Cui X, Siebert R, Gesk S et al. Inv(2)(p23q35) in anaplastic large-cell lymphoma induces constitutive anaplastic lymphoma kinase (ALK) tyrosine kinase activation by fusion to ATIC, an enzyme involved in purine nucleotide biosynthesis. Blood 2000; 95: 2144\u20132149.","journal-title":"Blood"},{"key":"BFbcj20128_CR204","first-page":"793","volume":"60","author":"M Trinei","year":"2000","unstructured":"Trinei M, Lanfrancone L, Campo E, Pulford K, Mason DY, Pelicci PG et al. A new variant anaplastic lymphoma kinase (ALK)-fusion protein (ATIC-ALK) in a case of ALK-positive anaplastic large cell lymphoma. Cancer Res 2000; 60: 793\u2013798.","journal-title":"Cancer Res"},{"key":"BFbcj20128_CR205","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1016\/S0002-9440(10)61711-7","volume":"159","author":"JA Bridge","year":"2001","unstructured":"Bridge JA, Kanamori M, Ma Z, Pickering D, Hill DA, Lydiatt W et al. Fusion of the ALK gene to the clathrin heavy chain gene, CLTC, in inflammatory myofibroblastic tumor. Am J Pathol 2001; 159: 411\u2013415.","journal-title":"Am J Pathol"},{"key":"BFbcj20128_CR206","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1038\/modpathol.3800742","volume":"20","author":"KK Reichard","year":"2007","unstructured":"Reichard KK, McKenna RW, Kroft SH . ALK-positive diffuse large B-cell lymphoma: report of four cases and review of the literature. Mod Pathol 2007; 20: 310\u2013319.","journal-title":"Mod Pathol"},{"key":"BFbcj20128_CR207","doi-asserted-by":"crossref","first-page":"3204","DOI":"10.1182\/blood.V95.10.3204","volume":"95","author":"C Touriol","year":"2000","unstructured":"Touriol C, Greenland C, Lamant L, Pulford K, Bernard F, Rousset T et al. Further demonstration of the diversity of chromosomal changes involving 2p23 in ALK-positive lymphoma: 2 cases expressing ALK kinase fused to CLTCL (clathrin chain polypeptide-like). Blood 2000; 95: 3204\u20133207.","journal-title":"Blood"},{"key":"BFbcj20128_CR208","doi-asserted-by":"crossref","first-page":"1038","DOI":"10.1016\/j.humpath.2004.05.006","volume":"35","author":"F Tort","year":"2004","unstructured":"Tort F, Campo E, Pohlman B, Hsi E . Heterogeneity of genomic breakpoints in MSN-ALK translocations in anaplastic large cell lymphoma. Hum Pathol 2004; 35: 1038\u20131041.","journal-title":"Hum Pathol"},{"key":"BFbcj20128_CR209","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1038\/labinvest.3780249","volume":"81","author":"F Tort","year":"2001","unstructured":"Tort F, Pinyol M, Pulford K, Roncador G, Hernandez L, Nayach I et al. Molecular characterization of a new ALK translocation involving moesin (MSN-ALK) in anaplastic large cell lymphoma. Lab Invest 2001; 81: 419\u2013426.","journal-title":"Lab Invest"},{"key":"BFbcj20128_CR210","doi-asserted-by":"crossref","first-page":"1209","DOI":"10.1182\/blood.V98.4.1209","volume":"98","author":"SJ Meech","year":"2001","unstructured":"Meech SJ, McGavran L, Odom LF, Liang X, Meltesen L, Gump J et al. Unusual childhood extramedullary hematologic malignancy with natural killer cell properties that contains tropomyosin 4--anaplastic lymphoma kinase gene fusion. Blood 2001; 98: 1209\u20131216.","journal-title":"Blood"},{"key":"BFbcj20128_CR211","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1002\/gcc.10033","volume":"34","author":"J Cools","year":"2002","unstructured":"Cools J, Wlodarska I, Somers R, Mentens N, Pedeutour F, Maes B et al. Identification of novel fusion partners of ALK, the anaplastic lymphoma kinase, in anaplastic large-cell lymphoma and inflammatory myofibroblastic tumor. Genes Chromosomes Cancer 2002; 34: 354\u2013362.","journal-title":"Genes Chromosomes Cancer"},{"key":"BFbcj20128_CR212","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1002\/gcc.10177","volume":"37","author":"Z Ma","year":"2003","unstructured":"Ma Z, Hill DA, Collins MH, Morris SW, Sumegi J, Zhou M et al. Fusion of ALK to the Ran-binding protein 2 (RANBP2) gene in inflammatory myofibroblastic tumor. Genes Chromosomes Cancer 2003; 37: 98\u2013105.","journal-title":"Genes Chromosomes Cancer"},{"key":"BFbcj20128_CR213","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1002\/gcc.10232","volume":"37","author":"L Lamant","year":"2003","unstructured":"Lamant L, Gascoyne RD, Duplantier MM, Armstrong F, Raghab A, Chhanabhai M et al. Non-muscle myosin heavy chain (MYH9): a new partner fused to ALK in anaplastic large cell lymphoma. Genes Chromosomes Cancer 2003; 37: 427\u2013432.","journal-title":"Genes Chromosomes Cancer"},{"key":"BFbcj20128_CR214","doi-asserted-by":"crossref","first-page":"1255","DOI":"10.1097\/01.LAB.0000088856.49388.EA","volume":"83","author":"LV Debelenko","year":"2003","unstructured":"Debelenko LV, Arthur DC, Pack SD, Helman LJ, Schrump DS, Tsokos M . Identification of CARS-ALK fusion in primary and metastatic lesions of an inflammatory myofibroblastic tumor. Lab Invest 2003; 83: 1255\u20131265.","journal-title":"Lab Invest"},{"key":"BFbcj20128_CR215","doi-asserted-by":"crossref","first-page":"940","DOI":"10.1016\/j.humpath.2006.12.019","volume":"38","author":"D Stachurski","year":"2007","unstructured":"Stachurski D, Miron PM, Al-Homsi S, Hutchinson L, Harris NL, Woda B et al. Anaplastic lymphoma kinase-positive diffuse large B-cell lymphoma with a complex karyotype and cryptic 3\u2032 ALK gene insertion to chromosome 4 q22\u201324. Hum Pathol 2007; 38: 940\u2013945.","journal-title":"Hum Pathol"},{"key":"BFbcj20128_CR216","doi-asserted-by":"crossref","first-page":"1181","DOI":"10.1002\/ijc.21490","volume":"118","author":"I Panagopoulos","year":"2006","unstructured":"Panagopoulos I, Nilsson T, Domanski HA, Isaksson M, Lindblom P, Mertens F et al. Fusion of the SEC31L1 and ALK genes in an inflammatory myofibroblastic tumor. Int J Cancer 2006; 118: 1181\u20131186.","journal-title":"Int J Cancer"},{"key":"BFbcj20128_CR217","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1038\/nature05945","volume":"448","author":"M Soda","year":"2007","unstructured":"Soda M, Choi YL, Enomoto M, Takada S, Yamashita Y, Ishikawa S et al. Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer. Nature 2007; 448: 561\u2013566.","journal-title":"Nature"}],"container-title":["Blood Cancer Journal"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nature.com\/articles\/bcj20128.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/bcj20128","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/bcj20128.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,1,5]],"date-time":"2023-01-05T22:45:56Z","timestamp":1672958756000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/bcj20128"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,4,13]]},"references-count":217,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2012,4]]}},"alternative-id":["BFbcj20128"],"URL":"https:\/\/doi.org\/10.1038\/bcj.2012.8","relation":{},"ISSN":["2044-5385"],"issn-type":[{"value":"2044-5385","type":"electronic"}],"subject":[],"published":{"date-parts":[[2012,4,13]]},"assertion":[{"value":"24 June 2011","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 December 2011","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 February 2012","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 April 2012","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"AAF has sponsored research from Merck and Pfizer on the use of GSIs for the treatment of T-ALL. The remaining authors declare no conflict of interest.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}